10-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 10-K
X	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
	SECURITIES EXCHANGE ACT OF 1934

For the year ended December 31, 2004
OR
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
	SECURITIES EXCHANGE ACT OF 1934
For the transition period from				to
Commission file number 1-7928
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware					94-1381833
(State or other jurisdiction of incorporation or organization)					(I.R.S. Employer Identification No.)
1000 Alfred Nobel Drive, Hercules, California						94547
(Address of principal executive offices)						(Zip Code)
(510)724-7000
Registrant's telephone number, including area code
Securities registered pursuant to Section 12 (b) of the Act:
Title of Each Class		Name of Each Exchange on Which Registered	Shares Outstanding February 15, 2005					Market  Value on February 15, 2005 of Stocks Held by  Non-Affiliates
Class A Common Stock Par Value $0.0001 per share		American Stock Exchange	21,043,099					$ 1,001,218,565
Class B Common Stock Par Value $0.0001 per share		American Stock Exchange	4,848,378					$ 30,028,939
Securities registered pursuant to Section 12 (g) of the Act:     NONE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months,  for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days
							Yes    X        No  _____
Indicate by check if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not  contained herein,
And will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of the Form 10-K or any amendment to this Form 10-K.{   }
Indicated by check mark whether the registrant is an accelerated filer ( as defined in Rule 126-2 of the Act)
							Yes    X       No  _____

Documents Incorporated by Reference

	Document	Form 10-K Parts
(1)	Annual Report to Stockholders for the fiscal year
	ended December 31, 2004 (specified portions)	I, II, IV
(2)	Definitive Proxy Statement to be mailed to stockholders
	in connection with the registrant's 2005 Annual Meeting
	of Stockholders (specified portions)	III

1

P A R T  I

ITEM 1. BUSINESS

General

Founded in 1957, Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company") was initially engaged in the development and produc­tion of specialty chemicals used in biochemical, pharmaceutical and other life science research applications.  In 1967, the Com­pany entered the field of clinical diagnostics with the develop­ment of its first test kit based on separation techniques and materials developed for life science research.  Recognizing that the fields of clinical diagnostics and life science research were evolving toward more automated techniques, Bio-Rad expanded into the field of analytical and measuring instrument systems through internal research and development efforts and acquisitions in the late 1970's and 1980's.

As Bio-Rad broadened its product lines, it also expanded its geographical market.  The Company has distribution chan­nels in over thirty countries outside the United States through subsidiaries whose primary focus is customer service and product distribution.

On October 1, 1999 Bio-Rad acquired the stock of Pasteur Sanofi Diagnostics (PSD) and the rights to certain ancillary assets for $210 million.  PSD was founded by the Institut Pasteur to commercialize its diagnostic research, and held certain exclusive licenses from the Institut Pasteur in the HIV and infectious disease diagnostic product market.  PSD also expanded the geographic reach and market penetration for the Company's products particularly in Latin America, Africa and France.

Bio-Rad manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Description of Business

Business Segments

The Company operates in two industry segments designated as Life Science and Clinical Diagnostics.  Each operates in both the United States and international markets.  For a description of business and financial information on industry and geographic segments, see Note 15 on pages 29 through 32 of Exhibit 13.1, which is incorporated herein by reference.

2

Life Science Segment.

Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems.  Life science researchers use a variety of products and systems-- including reagents, instruments, software and apparatus-- to advance the study of life processes, drug discovery, biotechnology and food pathogen testing, primarily within a laboratory setting.

We focus on selected segments of the life science market all dealing with functional genomics and proteomics and which we estimate 2004 worldwide sales totaled approximately $4 billion.  The primary technological applications that we supply to these segments consist of electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation and amplification. The primary end-users in our sectors of the market are universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers and food testing laboratories.

Clinical Diagnostics Segment.

The clinical diagnostics industry encompasses a broad array of technologies incorporated into a variety of tests used to detect, identify and quantify substances in blood or other bodily fluids and tissues.  The test results are used as aids for medical diagnosis, detection, evaluation, monitoring and treatment of diseases and other medical conditions.  The bulk of tests are performed in vitro (outside the body), while the remainder consist of in vivo ("in the body") tests.  The most common type of in vitro tests are routine chemistry tests that measure important health parameters, such as glucose, cholesterol or sodium, as part of routine blood checks.  Other diagnostic tests are more specialized and require more sophisticated equipment and materials than do routine tests.  These specialized tests are typically lower-volume and higher-priced than routine tests.  We estimate that in 2004 the global clinical diagnostics market totaled approximately $24.0 billion.

The primary end-users in the areas of the clinical diagnostics industry we target are hospital laboratories, reference laboratories, physician office laboratories, government agencies and other diagnostics manufacturers.

3

Raw Materials and Components

The Company utilizes a wide variety of chemicals, biological materials, electronic components, machined metal parts, optical parts, minicomputers and peripheral devices.  Most of these materials and components are available from numerous sources and the Company has not experienced difficulty in securing adequate

supplies.

Patents and Trademarks

We own numerous U.S. and international patents and patent licenses.  We believe, however, that our ability to develop and manufacture our products depends primarily on our knowledge, technology and special skills.  Under several patent license agreements, we pay royalties on the sales of certain products.  We view these patents and license agreements as valuable assets.

Seasonal Operations and Backlog

The Company's business is not inherently seasonal, however, the European custom of concentrating vacation during the summer months usually tempers third quarter sales volume and operating income.

For the most part, the Company operates in markets characterized by short lead times and the absence of significant backlogs.  Management has concluded that backlog information is not material to the Company's business as a whole.

Sales and Marketing

Each of Bio-Rad's segments maintains a sales force to sell its products on a direct basis.  Each sales force is technically trained in the disciplines associated with its products.  Sales are also generated through direct mail advertising, exhibits at trade shows and technical meetings, telemarketing, e-commerce and by extensive advertising in technical and trade publications.  Sales and marketing efforts are augmented by technical service departments that assist customers in effective product utilization and in new product applications.  Bio-Rad also produces and distributes technical literature and holds seminars for customers on the use of its products.  

4

Our customer base is broad and diversified.  In 2004, no single customer accounted for more than 2% of our total net sales.  Our sales are affected by certain external factors.  For example, a number of our customers, particularly in the Life Science segment, are substantially dependent on government grants and research contracts for their funding. A significant reduction of government funding would have a detrimental effect on the results of this segment.

The Company is the leading provider of BSE (Bovine Spongiform Encephalopathy or mad cow) tests throughout the world.  Revenues from the sales of testing products for BSE within our Life Science segment represented approximately 11% of consolidated net revenue in 2004 and 2003.  A large portion of the revenue for this product is from government agencies currently mandating the use of the test.  Competition, pricing, changes in test standards, technology or a decrease in government demand could negatively impact the Company's future revenue from this product.  

Most of the Company's international sales are generated by wholly-owned subsidiaries and their branch offices.  Certain of these subsidiaries also have manufacturing facilities.  While Bio-Rad's international operations are subject to certain risks common to foreign operations in general, such as changes in governmental regulations, import restrictions and foreign exchange fluctuations, the Company's international operations are principally in developed nations, which the Company regards as presenting no significantly greater risks to its operations than are present in the United States.

Competition

Most markets served by our product groups are competitive.  Our competitors range in size from start-ups to large multinational corporations. Reliable independent information on sales and market share of products produced by our competitors is not generally available.  We believe, however, based on our own marketing information, that while some competitors are dominant with respect to certain individual products, no one company, including us, is dominant with respect to a material portion of any segment of our business.

5

Because of the breadth of its product lines, Life Science does not face the same competitor for all of its products.  Competitors in this market include GE Biosciences, Invitrogen, Qiagen, and Applied BioSystems (Applera).  We compete primarily based on meeting performance specifications.

Competitors in the Clinical Diagnostics segment range in size from small private companies to large multinational corporations. We compete mainly in specific market niches and do not attempt to pursue the most competitive general diagnostics markets.  We compete based on our technological ability to provide customers with very specific tests and believe we are usually a significant competitor within our market niche.  Competitors include Abbott Laboratories, bioMerieux, Inc., Roche Diagnostics, BioChem Pharma, Inova, diaSorin and Medical Analysis Systems.

Product Research and Development

The Company conducts extensive product research and development activities in all areas of our business, employing approximately 700 people worldwide in these activities.  Research and development have played a major role in Bio-Rad's growth and are expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development and testing of new products and applications, we consult with scientific and medical professionals at universities, hospitals and medical schools, and in industry.  Excluding in-process research and development, we spent approximately $108.3 million, $91.3 million and $79.8 million on research and development activities during the years ended December 31, 2004, 2003 and 2002 respectively.

Regulatory Matters

The manufacturing, marketing and labeling of certain of our products (primarily diagnostic products) are subject to regulation in the United States by the Center for Devices and Radiological Health of the United States Food and Drug Administration (FDA) and in other jurisdictions by state and foreign government authorities.  FDA regulations require that some new products have pre-marketing approval by the FDA and require certain products to be manufactured in accordance with "good manufacturing practices," to be extensively tested and to be properly labeled to disclose test results and performance claims and limitations.

6

As a multinational manufacturer and distributor of sophisticated instrumentation equipment, we must meet a wide array of electromagnetic compatibility and safety compliance requirements to satisfy regulations in the United States, the European Community and other jurisdictions.  These requirements relating to testing and trials, product licensing, pricing and reimbursement vary widely among countries.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liabilities and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties.

Employees

At  January 31, 2005 Bio-Rad had approximately 5,200 full-time employees.  Fewer than 9% of Bio-Rad's approximately 2,700 U. S. employees are covered by a collective bargaining agreement which will expire on November 7, 2006.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.  Bio-Rad considers its employee relations in general to be good.

Available Information

The Company files annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934.  The public may read and copy any materials that the Company files with the SEC at the SEC's Public Reference Room at 450 Fifth Street, NW, Washington, DC 20549.  The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  Also, the SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including the Company, that file electronically with the SEC.  The public can obtain any documents that the Company files with the SEC at http://www.sec.gov.

7

The Company's website address is www.bio-rad.com.  The Company makes available, free of charge through its Internet website, its Form 10-K's, 10-Q's and 8-K's, and any amendments to these forms, as soon as reasonably practicable after filing with the SEC.

ITEM 2. PROPERTIES

We own our Corporate headquarters located in Hercules, California.  The principal manufacturing and research locations for each segment are as follows:

Segment	Location	Owned/Leased
Life Science	Richmond, California	Owned/Leased
	Hercules, California	Owned/Leased
	Waltham, Massachusetts	Leased
	Milan, Italy	Leased
	Riom, France	Owned/Leased
Clinical
Diagnostics	Hercules, California	Owned/Leased
	Irvine, California	Leased
	Greater Seattle, Washington	Owned/Leased
	Plano, Texas	Leased
	Lille, France	Owned
	Paris, France	Leased
	Munich, Germany	Leased
	Nazareth-Eke, Belgium	Leased

Most manufacturing and research facilities also house administration, sales and distribution activities.  In addition, we lease office and warehouse facilities in a variety of locations around the world.  The facilities are used principally for sales, service, distribution and administration for both segments.

The Marnes la Coquette facility near Paris, France serves as a significant manufacturing, administrative and research facility.  The lease expires at December 31, 2005.  The Company believes it will successfully conclude negotiations to extend the lease for several years.   

The Company recently completed building additional facilities at its Northern California headquarters.  Historically, adequate space to expand sales and distribution channels has been available and we have leased space as needed.

8

ITEM 3.  LEGAL PROCEEDINGS

Note 14, "Legal Proceedings," appearing on page 27 of the Exhibit 13.1 is incorporated herein by reference.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no matters submitted to a vote of the Company's security holders during the fourth quarter of the fiscal year covered by this report.

P A R T  II

ITEM 5.  MARKET FOR REGISTRANT'S COMMON STOCK AND RELATED  

               STOCKHOLDER MATTERS AND ISSUER PURCHASES OF

               EQUITY SECURITIES

Information Concerning Common Stock

The Company's Class A and Class B Common Stock are listed on the American Stock Exchange with the symbols BIO and BIO.B, respectively.  The following sets forth, for the periods indicated, the high and low prices for the Company's Class A and Class B Common Stock.

	Class A		Class B
	High	Low	High	Low
2004
Fourth Quarter	59.50	50.06	58.25	50.90
Third Quarter	58.50	50.01	57.25	50.25
Second Quarter	61.90	55.15	61.00	55.50
First Quarter	58.79	51.81	59.00	52.00
2003
Fourth Quarter	65.00	48.81	65.10	47.95
Third Quarter	62.50	48.52	63.00	50.00
Second Quarter	62.85	35.35	61.00	35.00
First Quarter	39.11	33.20	44.35	32.00

On February 15, 2005 the Company had 446 holders of record of Class A Common Stock and 198 holders of record of Class B Common Stock. Bio-Rad has never paid a cash dividend and has no present plans to pay cash dividends.

See Item 12 for the security ownership of certain beneficial owners and management.

9

ITEM 6.  SELECTED FINANCIAL DATA

The table headed "Summary of Operations and Selected Financial Data" appearing on page 1 of Exhibit 13.1 is incorporated herein by reference.

ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL

 CONDITION AND RESULTS OF OPERATIONS

The section headed "Management's Discussion and Analysis of Results of Operations and Financial Condition" appearing on pages 35 through 46 of Exhibit 13.1 is incorporated herein by reference.

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT

MARKET RISK

The section headed "Financial Risk Management" appearing on pages 45 and 46 of Exhibit 13.1 is incorporated herein by reference.

ITEM 8

 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The Consolidated Financial Statements and Notes thereto and the Report of Independent Registered Public Accounting Firm appearing on pages 2 through 34 of Exhibit 13.1 are incorporated herein by reference.

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON

ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9a.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and the Company’s Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures.  Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective to provide reasonable assurance that material information relating to the Company is made known to management, including the Chief Executive Officer and Chief Financial Officer.

10

Changes in Internal Control Over Financial Reporting

There has been no change in the Company’s internal controls over financial reporting during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal controls over financial reporting.

Management’s Report on Internal Control Over Financial Reporting

The management of Bio-Rad Laboratories is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”).  The Company’s internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of the Company’s financial statements presented in accordance with generally accepted accounting principles.

An internal control system over financial reporting has inherent limitations and may not prevent or detect misstatements.  Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

We excluded MJ Geneworks, Inc. from our assessment of internal control over financial reporting as of December 31, 2004 because it was acquired by Bio-Rad in the third quarter of 2004.  MJ Geneworks constituted less than 5% of total assets as of December 31, 2004 and less than 5% of total revenues and net earnings for the year then ended.  Refer to Note 2 to the consolidated financial statements for further discussion of this acquisition and its impact on Bio-Rad’s consolidated financial statements.  Notwithstanding the exclusion of MJ Geneworks from our assessment, there was no material change to our internal control over financial reporting due to the acquisition pursuant to Rule 15d-15 of the Exchange Act.  Our assessment of internal control over financial reporting for fiscal year 2005 will include MJ Geneworks.

Management has used the framework set forth in the report entitled “Internal Control – Integrated Framework” published by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission to evaluate the effectiveness of the Company’s internal control over financial reporting as of December 31, 2004.  Management has concluded the Company’s internal control over financial reporting was effective as of December 31, 2004.  The Company’s independent auditor, Deloitte and Touche LLP, has issued an attestation report on management’s assessment of the Company’s internal control over financial reporting.

11

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ON INTERNAL CONTROLS OVER FINANCIAL REPORTING

To the Board of Directors and Stockholders of

Bio-Rad Laboratories, Inc.

Hercules, California

We have audited management’s assessment, included in the accompanying Management’s Report on Internal Control Over Financial Reporting, that Bio-Rad Laboratories, Inc. and subsidiaries (the “Company”) maintained effective internal control over financial reporting as of December 31, 2004, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.  As described in Management’s Report on Internal Control Over Financial Reporting, management excluded from their assessment the internal control over financial reporting at MJ Geneworks, Inc. and its subsidiaries (“MJ Geneworks”), which was acquired on August 17, 2004 and whose financial statements reflect less than 5% of total consolidated assets as of December 31, 2004 and less than 5% of consolidated revenues and net earnings for the year then ended. &nbs p;Accordingly, our audit did not include the internal control over financial reporting at MJ Geneworks.  The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting.  Our responsibility is to express an opinion on management’s assessment and an opinion on the effectiveness of the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  Our audit included obtaining an understanding of internal control over financial reporting, evaluating management’s assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances.  We believe that our audit provides a reasonable basis for our opinions.

12

A company’s internal control over financial reporting is a process designed by, or under the supervision of, the company’s principal executive and principal financial officers, or persons performing similar functions, and effected by the company’s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.  A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis.  Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, management’s assessment that the Company maintained effective internal control over financial reporting as of December 31, 2004, is fairly stated, in all material respects, based on the criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.  Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2004, based on the criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements and financial statement schedule as of and for the year ended December 31, 2004 of the Company and our reports dated March 2, 2005 expressed an unqualified opinion on those consolidated financial statements and financial statement schedule.

DELOITTE & TOUCHE LLP

San Francisco, California

March 2, 2005

13

ITEM 9b.

OTHER INFORMATION

None.

PART III

ITEM 10.

DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

The sections labeled "Election of Directors" and "Section 16(a) Beneficial Ownership Reporting Compliance" of the definitive Proxy Statement mailed to stockholders in connection with the 2005 Annual Meeting of Stockholders (the” 2005 Proxy Statement") are incorporated herein by reference.

The Company’s Board of Directors has determined that Philip L. Padou is an “audit committee financial expert,” as defined in Item 401(h) of Regulation S-K.  Mr. Padou is also an “independent” director, as determined in accordance with the independence standards set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 121A of the American Stock Exchange Company Guide.

The Company has adopted a code of business ethics and conduct that applies to its principal executive officer, principal financial officer, principal accounting officer or controller and all other employees.  The Company will provide a copy of the code of ethics to any person, without charge, upon request, by writing to the Company at “Bio-Rad Laboratories, Inc., Investor Relations, 1000 Alfred Nobel Drive, Hercules, CA  94547”.

14

ITEM 11.

EXECUTIVE COMPENSATION

The sections labeled "Executive Compensation and Other Information," "Compensation of Directors," "Compensation Committee Interlocks and Insider Participation," "Report of the Compensation Committee of the Board of Directors" and "Stock Performance Graph" of the 2005 Proxy Statement are incorporated herein by reference.

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

AND MANAGEMENT

The section labeled "Principal and Management Stockholders" of the 2005 Proxy Statement is incorporated herein by reference.

Plan category	(a) Number of securities  to be issued upon exercise of outstanding options,  warrants and rights	(b) Weighted-average exercise price of outstanding options, warrants  and rights	(c) Number of securities remaining available for future issuance  under equity compensation plans (excluding securities reflected in column (a))
Equity compensation plans approved by security holders (1)	1,611,089	$27.20	1,550,795	(2)
Equity compensation  plans not approved by stockholders	--	--	--
Total	1,611,089	$27.20	1,550,795

(1) Consists of the Bio-Rad Laboratories, Inc. 1994 Stock Option Plan, the 2003 Stock Option Plan and the Bio-Rad Laboratories, Inc. Amended and Restated 1988 Employee Stock Purchase Plan.

(2) Consists of 1,372,550 shares available under the 2003 Stock Option Plan and 178,245 shares available for issuance under the Bio-Rad Laboratories, Inc. Amended and Restated 1988 Employee Stock Purchase Plan.

15

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

The sections labeled "Certain Relationships and Related Party Transactions" and "Compensation of Directors" of the 2005 Proxy Statement are incorporated herein by reference.

ITEM 14.

PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item is incorporated by reference to the section entitled “Report of the Audit Committee of the Board of Directors” of the 2005 Proxy Statement.

16

P A R T  IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a) 1.	Index to Financial Statements
	The following Consolidated Financial Statements are included in Exhibit 13.1 and
	are incorporated herein by reference pursuant to Item 8:
		Page in
		Exhibit 13.1
	Consolidated Balance Sheets at December 31, 2004 and 2003	2-3
	Consolidated Statements of Income for each of the three years
	in the period ended December 31, 2004	4
	Consolidated Statements of Cash Flows for each of the
	three years in the period  ended December 31, 2004	5
	Consolidated Statements of Changes in Stockholders' Equity
	for each of the three years in the period ended December 31, 2004	6
	Notes to Consolidated Financial Statements	7-33
	Report of Independent Registered Public Accounting Firm	34
2.	Index to Financial Statement Schedule
		Page in
		Form 10-K
	Schedule II Valuation and Qualifying Accounts	18
	Report of Independent Registered Public Accounting Firm	19
All other financial statement schedules are omitted because they are not required or because
the required information is included in the Consolidated Financial Statements or the Notes thereto.
3.	Index to Exhibits
The exhibits listed in the accompanying Index to Exhibits on pages 22  through 25 of this report
are filed or incorporated by reference as part of this report.

17

BIO-RAD LABORATORIES, INC,.

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

Years Ended December 31, 2004, 2003 and 2002

(In thousands)

Reserve for doubtful accounts receivable

	Balance at Beginning of Year	Additions Charged to Costs and Expenses	Deductions	Other (A)	Balance at End of Year
2004	$12,978	$2,029	$   (621)	$(980)	$13,406
2003	$12,122	$4,687	$(3,831)	--	$12,978
2002	$11,509	$2,857	$(2,244)	--	$12,122

(A)  Due to the sale of the Company’s confocal microscopy product line.

Valuation allowance for current and long-term deferred tax assets

	Balance at Beginning of Year	Additions	Deductions Charged to Costs and Expenses	Other (B)	Balance at End of Year
2004	$21,446	$1,058	$(4,481)	--	$18,023
2003	$17,215	$4,240	$       (9)	--	$21,446
2002	$20,337	$2,783	$(2,571)	$(3,334)	$17,215

(B)

 Valuation arising from the acquisition of PSD.

18

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

Bio-Rad Laboratories, Inc.

Hercules, California

We have audited the consolidated financial statements of Bio-Rad Laboratories, Inc. and subsidiaries (the “Company”) as of December 31, 2004 and 2003, and for each of the three years in the period ended December 31, 2004, management’s assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2004, and the effectiveness of the Company’s internal control over financial reporting as of December 31, 2004, and have issued our reports thereon dated March 2, 2005; such consolidated financial statements and our report on such consolidated financial statements are included in your 2004 Annual Report to Stockholders and are incorporated herein by reference.  Our report relating to management’s report on the effectiveness of internal controls over financial reporting is included herein.  Our audits also included the consolidated financial statement schedule of the Company listed in Item 15(a)2.  This consolidated financial statement schedule is the responsibility of the Company’s management.  Our responsibility is to express an opinion based on our audits.  In our opinion, the consolidated financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, present fairly, in all material respects, the information set for therein.

DELOITTE & TOUCHE LLP

San Francisco, California

March 2, 2005

19

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-RAD LABORATORIES, INC.

By:_/s/ Sanford S. Wadler

Sanford S. Wadler

Secretary

Date:   March 2, 2005    

20

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Principal Executive Officer:
/s/ Norman Schwartz	President and Director	March 2, 2005
(Norman Schwartz)
Principal Financial Officer
/s/ Christine A. Tsingos___	Vice President,
(Christine A. Tsingos)	Chief Financial Officer	March 2, 2005
Principal Accounting Officer	Corporate Controller	March 2, 2005
/s/ James R. Stark________
(James R. Stark)
Other Directors:
/s/ James J. Bennett______	Director	March 2, 2005
(James J. Bennett)
/s/ Albert J. Hillman______	Director	March 2, 2005
(Albert J. Hillman)
/s/ Ruediger Naumann-Etienne	Director	March 2, 2005
(Ruediger Naumann-Etienne)
/s/ Philip L. Padou________	Director	March 2, 2005
(Philip L. Padou)
/s/ Alice N. Schwartz______
(Alice N. Schwartz)	Director	March 2, 2005
/s/ David Schwartz________	Director	March 2, 2005
(David Schwartz)

21

BIO-RAD LABORATORIES, INC.

INDEX TO EXHIBITS

ITEM 14(a)3

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed under the Securities Exchange Act of 1934.”

Exhibit No.

3.1

Restated Certificate of Incorporation, as of February 8, 2002. (1)

3.1.1

Certificate of Amendment to Restated Certificate of Incorporation of Bio-Rad Laboratories, Inc., as of May 6, 2004.

3.2

Bylaws of the Registrant, as amended February 19,1980. (2)

4.1

Credit Agreement dated as of September 9, 2003 among Bio-Rad Laboratories, Inc., the lenders, Bank One, N.A., as Administrative Agent, Wells Fargo Bank, N.A. And Union Bank of California, N.A., as Syndication Agents and ABN AMRO Bank N.V. and BNP Paribas, as Documentation Agents. (3)

4.1.1

Amendment No. 1 to Credit Agreement dated as of December 8, 2004 among Bio-Rad Laboratories, Inc., the lenders referred to herein, JPMorgan Chase Bank, N.A. (successor by merger to Bank One, NA (Illinois), as lender and Administrative Agent, Wells Fargo Bank, N.A. and Union Bank of California, N.A., as Syndication Agents and ABN AMRO Bank N.V. and BNP Paribas, as Documentation agents. (4)

4.2

Pledge Amendment dated as of September 9, 2003 among Bio-Rad Laboratories, Inc., and Bank One, N.A., as contractual representative.  (3)

4.3

Security Agreement dated as of September 9, 2003 among Bio-Rad Laboratories, Inc., as Grantor and Bank One N.A., as Administrative Agent. (3)

4.4

The Indenture dated as of August 11, 2003 for 7.50% Senior Subordinated Notes due 2013 among Bio-Rad Laboratories, Inc., as Issuer, and Wells Fargo Bank, N.A., as Trustee. (3)

22

4.5

The Exchange and Registration Rights Agreement dated as of August 11, 2003 for 7.50% Senior Subordinated Notes due 2013. (3)

4.6

Indenture, dated as of December 21, 2004, between Bio-Rad Laboratories, Inc. and Wells Fargo National Bank, as trustee. (5)

10.4

1994 Stock Option Plan. (6)

10.4.1

Amendment to the Bio-Rad Laboratories, Inc. 1994 Stock Option Plan dated April 28, 1998. (7)

10.4.2

Second Amendment to the Bio-Rad Laboratories, Inc. 1994 Stock Option Plan dated December 6, 1999. (7)

10.4.3

Third Amendment to the Bio-Rad Laboratories, Inc. 1994 Stock Option Plan dated September 19, 2000. (7)

10.4.4

Fourth Amendment to the Bio-Rad Laboratories, Inc. 1994 Stock Option Plan dated April 25, 2001.  (8)

10.5

Amended and Restated 1988 Employee Stock Purchase Plan. (9)

10.5.1

Amendment to the Amended 1988 Employee Stock Purchase Plan. (8)

10.6

Employees' Deferred Profit Sharing Retirement Plan (Amended and Restated effective January 1, 1997). (10)

10.7

2003 Stock Option Plan. (11)

10.10

Non-competition and employment continuation agreement with James J. Bennett. (10)

10.13

Stock Purchase Agreement dated as of August 16, 2004 by and between the Company, MJ GeneWorks, Incorporated, Michael J. Finney and John D. Finney, excluding exhibits and schedules.  Pursuant to Regulation S-K Item 601(b)(2), the exhibits and schedules to this agreement have not been filed.  The Company agrees to furnish supplementally a copy of any omitted exhibits or schedules to the SEC upon request.  The Company has requested confidential treatment of certain portions of this agreement. (12)

23

13.1

Excerpt from Annual Report to Stockholders' for the fiscal year ended December 31, 2004, (to be deemed filed only to the extent required by the instructions to exhibits for reports on Form 10-K).

21.1

Listing of Subsidiaries.

23.1

Consent of Independent Registered Public Accounting Firm.

31.1

Certification of Chief Executive Officer Required by Rule 13a(14(a) (17 CFR 240.13a-14(a)).

31.2

Certification of Chief Financial Officer Required by Rule 13a(14(a) (17 CFR 240.13a-14(a)).

32.1

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

______________________________________________________________

(1)

Incorporated by reference from Exhibits to the Company's Form 10-K filing for the fiscal year ended December 31, 2001, dated March 28, 2002.

(2)

Incorporated by reference from the Exhibits to the Company's Registration Statement on Form S-7 Registration No. 2-66797, which became effective

April 22, 1980.

(3)

Incorporated by reference from Exhibits to the Company's Form S-4 dated September 19, 2003.

24

(4)

Incorporated by reference from Exhibits to the Company’s Form 8-K filing dated December 14, 2004.

(5)

Incorporated by reference from Exhibits to the Company’s Form 8-K filing dated December 22, 2004.

(6)

Incorporated by reference from the Exhibits to the Company's Form S-8 filing, dated April 28, 1994.

(7)

Incorporated by reference from the Exhibits to the Company's Form  10-K filing for the fiscal year ended December 31, 2000, dated March 28, 2001.

(8)

Incorporated by reference from the Exhibits to the Company's Form  10-K filing for the fiscal year ended December 31, 2003, dated March 15, 2004.

(9)

Incorporated by reference from the Exhibits to the Company's September 30, 1998, Form 10-Q filing dated November 12, 1998.

(10)

         Incorporated by reference from the Exhibits to the Company's September 30, 1997, Form 10-Q filing dated November 13, 1997.

(11)

Incorporated by reference from Exhibits to the Company’s March 31, 2003, Form 10-Q filing dated May 13, 2003.

(12)

Incorporated by reference from Exhibits to the Company’s September 30, 2004, Form 10-Q filing dated November 9, 2004.

25

EX-3

Exhibit 3.1.1

CERTIFICATE OF AMENDMENT

TO

RESTATED

CERTIFICATE OF INCORPORATION

OF

BIO-RAD LABORATORIES, INC.

(a Delaware Corporation)

Bio-Rad Laboratories, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify:

1.

The name of the corporation (hereinafter called the “Corporation”) is Bio-Rad Laboratories, Inc.

2.  

The Restated Certificate of Incorporation of the Corporation is hereby amended by striking out Section 4(a) thereof and by substituting in lieu thereof the following new Section 4(a):

“The total number of shares of all classes of stock which the corporation shall be authorized to issue is 107,500,000 shares, divided into three classes of shares of stock as follows:  80,000,000 shares of Class A Common Stock, par value $0.0001 per share (“Class A Common”), 20,000,000 shares of Class B Common Stock, par value $0.0001 per share (“Class B Common”), and 7,500,000 shares of Preferred Stock, par value $0.0001 per share (“Preferred Stock”).”  

3.

The amendment of the Restated Certificate of Incorporation of the Corporation herein certified has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, Bio-Rad Laboratories, Inc. has caused this certificate to be executed by Norman D. Schwartz, its President and Chief Executive Officer, and Sanford S. Wadler, its Vice President, General Counsel and Secretary, this 6th day of May, 2004.

     /s/ Norman D. Schwartz

Norman D. Schwartz, President and Chief Executive Officer

    /s/ Sanford S. Wadler

Sanford S. Wadler, Vice President, General Counsel and Secretary

EX-13

Bio-Rad Laboratories, Inc.

Summary of Operations and Selected Financial Data (in thousands, except per share data)

	Year Ended,
	2004	2003	2002	2001	2000
Net sales	$ 1,090,012	$ 979,631	$ 865,006	$ 789,639	$ 700,664
Cost of goods sold	479,939	423,401	365,451	345,964	333,092
Gross profit	610,073	556,230	499,555	443,675	367,572
Selling, general and administrative expense	378,264	317,524	281,579	257,684	238,947
Product research and development expense	108,344	91,273	79,788	73,922	65,742
Purchased in-process research and development expense	14,620	--	--	--	--
Goodwill amortization	--	--	--	7,746	8,109
Loss (gain) on divestitures	--	--	--	5,150	(21,845)
Interest expense	20,219	31,006	28,207	24,088	30,612
Foreign exchange losses	2,394	4,080	5,441	2,097	420
Other (income) expense, net (1)	(11,095)	(3,012)	(678)	10,031	689
Income from continuing operations before taxes
and cumulative effect of change in accounting principle	97,327	115,359	105,218	62,957	44,898
Provision for income taxes	(31,035)	(38,055)	(36,692)	(20,132)	(13,423)
Income from continuing operations before cumulative
effect of change in accounting principle	66,292	77,304	68,526	42,825	31,475
Cumulative effect of change in accounting principle (2)	---	---	--	--	(710)
Income from continuing operations	66,292	77,304	68,526	42,825	30,765
Discontinued operations
Gain (loss) from discontinued operations (net of tax)	(1,487)	(1,133)	(663)	1,354	335
Gain on divestiture (net of tax)	3,437	--	--	--	--
Total income (loss) from discontinued operations	1,950	(1,133)	(663)	1,354	335
Net income	$   68,242	$   76,171	$  67,863	$   44,179	$  31,100
Basic earnings per share:
Continuing operations before cumulative effect of
change in accounting principle	$ 2.58	$ 3.04	$ 2.73	$ 1.74	$ 1.29
Cumulative effect of change in accounting principle (2)	--	--	--	--	(0.03)
Discontinued operations	0.07	(0.04)	(0.03)	0.05	0.01
Basic earnings per share	$ 2.65	$ 3.00	$2.70	$ 1.79	$ 1.27
Diluted earnings per share:
Continuing operations before cumulative effect of
change in accounting principle	$ 2.51	$2.94	$2.63	$1.68	$1.29
Cumulative effect of change in accounting principle (2)	--	--	--	--	(0.03)
Discontinued operations	0.07	(0.04)	(0.02)	0.06	0.01
Diluted earnings per share	$ 2.58	$ 2.90	$ 2.61	$ 1.74	$ 1.27
Cash dividends paid per common share	--	--	--	--	--
Total assets	$1,392,002	$ 992,596	$720,703	$ 684,028	$ 646,278
Long-term debt, net of current maturities	$  425,979	$ 225,835	$105,768	$ 188,423	$ 203,360

(1) See Note 11 to the consolidated financial statements for components of Other (income) expense, net.  Included in 2001 is a $9.4 million writedown of an investment.

(2) Cumulative effect of accounting change per SEC Staff Accounting Bulletin 101, on Revenue Recognition.

1

Bio-Rad Laboratories, Inc.

Consolidated Balance Sheets
(in thousands)
	December 31,
		2004	2003
ASSETS
Current assets:
Cash and cash equivalents		$    195,734	$    65,395
Short-term investments		165,899	83,247
Accounts receivable less allowance of
$13,406 in 2004 and $12,978 in 2003		261,243	234,085
Inventories, net:
Raw materials		44,950	38,783
Work in process		48,206	38,798
Finished goods		112,356	112,677
Total inventories		205,512	190,258
Deferred tax assets		34,492	31,056
Prepaid expenses and other current assets		48,344	51,357
Total current assets		911,224	655,398
Property, plant and equipment:
Land and improvements		9,959	9,882
Buildings and leasehold improvements		119,433	105,963
Equipment		321,215	273,121
Total property, plant and equipment		450,607	388,966
Accumulated depreciation		(248,283)	(209,843)
Property, plant and equipment, net		202,324	179,123
Goodwill		113,276	69,503
Purchased intangibles, net		58,638	12,251
Long-term deferred tax assets		26,544	21,218
Other assets		79,996	55,103
TOTAL ASSETS		$1,392,002	$  992,596

 The accompanying notes are an integral part of these statements.

2

Bio-Rad Laboratories, Inc.

Consolidated Balance Sheets
(in thousands, except share data)
	December 31,
	2004	2003
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$     71,194	$  53,995
Accrued payroll and employee benefits	79,061	71,650
Notes payable	9,055	10,215
Current maturities of long-term debt	402	208
Sales, income and other taxes payable	15,835	20,833
Litigation accrual	50,000	--
Accrued royalties	39,317	34,168
Other current liabilities	50,511	48,183
Total current liabilities	315,375	239,252
Long-term debt, net of current maturities	425,979	225,835
Deferred tax liabilities	24,772	14,803
Other long-term liabilities	28,988	16,899
Total liabilities	795,114	496,789
Commitments and contingent liabilities	--	--
Stockholders’ equity:
Preferred stock, $0.0001 par value, 7,500,000
shares authorized; none outstanding	--	--
Class A common stock, $0.0001 par value, 80,000,000 shares
authorized; outstanding-20,997,568 at 2004; 50,000,000 shares	2	2
authorized; outstanding– 20,709,127 at 2003
Class B common stock, $0.0001 par value,
20,000,000 shares authorized; outstanding
2004 – 4,836,540; 2003 - 4,834,290	1	1
Additional paid-in capital	49,628	42,164
Retained earnings	489,254	421,012
Accumulated other comprehensive income:
Currency translation and other	58,003	32,628
Total stockholders’ equity	596,888	495,807
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 1,392,002	$  992,596

The accompanying notes are an integral part of these statements.

3

Bio-Rad Laboratories, Inc. Consolidated Statements of Income (in thousands, except per share data)
	Year Ended December 31,
		2004	2003	2002
Net sales		$ 1,090,012	$   979,631	$   865,006
Cost of good sold		479,939	423,401	365,451
Gross profit		610,073	556,230	499,555
Selling, general and administrative expense		378,264	317,524	281,579
Product research and development expense		108,344	91,273	79,788
Purchased in-process research and development expense		14,620	--	--
Interest expense		20,219	31,006	28,207
Foreign exchange losses		2,394	4,080	5,441
Other income, net		(11,095)	(3,012)	(678)
Income from continuing operations before taxes		97,327	115,359	105,218
Provision for income taxes		(31,035)	(38,055)	(36,692)
Income from continuing operations		66,292	77,304	68,526
Discontinued operations
Loss from discontinued operations net of tax benefits
of $532 in 2004, $538 in 2003 and $150 in 2002		(1,487)	(1,133)	(663)
Gain on divestiture net of tax expense of $2,295		3,437	--	--
Total income (loss) from discontinued operations		1,950	(1,133)	(663)
Net income		$    68,242	$   76,171	$   67,863
Basic earnings per share:
Continuing operations		$ 2.58	$ 3.04	$ 2.73
Discontinued operations		0.07	(0.04)	(0.03)
Net income		$ 2.65	$  3.00	$  2.70
Weighted average common shares		25,724	25,416	25,104
Diluted earnings per share:
Continuing operations		$ 2.51	$ 2.94	$ 2.63
Discontinued operations		0.07	(0.04)	(0.02)
Net income		$ 2.58	$  2.90	$  2.61
Weighted average common shares		26,489	26,310	26,021
The accompanying notes are an integral part of these statements.

4

Bio-Rad Laboratories, Inc.

Consolidated Statements of Cash Flows

(in thousands)
	Year Ended December 31,
		2004		2003		2002
Cash flows from operating activities:
Cash received from customers	$	1,081,645	$	996,384	$	858,121
Cash paid to suppliers and employees		(912,286)		(800,633)		(682,814)
Interest paid		(19,543)		(17,088)		(25,832)
Income tax payments		(33,637)		(51,280)		(43,016)
Miscellaneous receipts		8,933		1,928		112
Discontinued operations		(2,019)		(1,671)		(813)
Net cash provided by operating activities		123,093		127,640		105,758
Cash flows from investing activities:
Capital expenditures, net		(60,493)		(69,003)		(42,224)
Payments for acquisitions and investments		(58,983)		(16,375)		(8,568)
Proceeds from divestiture		19,775		--		--
Payments for purchase of intangible assets		(10,000)		--		--
Purchases of marketable securities and investments		(2,257,694)		(600,000)		(1,887)
Sales of marketable securities and investments		2,174,538		510,135		493
Foreign currency economic hedges, net		6,539		(14,998)		(2,270)
Net cash used in investing activities		(186,318)		(190,241)		(54,456)
Cash flows from financing activities:
Net borrowings (payments) on notes payable		(9,580)		435		5,031
Long-term borrowings		200,000		249,335		44,025
Payments on long-term debt		(1,781)		(132,012)		(133,517)
Debt retirement costs on 11-5/8% bonds		--		(9,467)		--
Debt issuance costs on 7.5% bonds		--		(5,431)		--
Debt issuance costs on 6.125% bonds		(2,876)		--		--
Proceeds from issuance of common stock		7,464		5,309		3,047
Reissuance of treasury stock		--		--		2,287
Net cash provided by (used in) financing activities		193,227		108,169		(79,127)
Effect of exchange rate changes on cash		337		(7,906)		8,429
Net increase (decrease) in cash and cash equivalents		130,339		37,662		(19,396)
Cash and cash equivalents at beginning of year		65,395		27,733		47,129
Cash and cash equivalents at end of year	$	195,734	$	65,395	$	27,733

The accompanying notes are an integral part of these statements.

5

Bio-Rad Laboratories, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

(in thousands)
	Year Ended December 31,
	2004	2003	2002
Common Stock, $0.0001 par value:
Balance at beginning of year	$         3	$          3	$           2
Issuance of common stock	--	--	1
Balance at end of year	3	3	3
Additional Paid-In Capital:
Balance at beginning of year	42,164	36,141	32,171
Issuance of common stock	6,250	5,309	3,047
Tax benefit from exercise of stock options	1,214	714	923
Balance at end of year	49,628	42,164	36,141
Treasury Stock:
Balance at beginning of year	--	--	(1,863)
Reissuance of treasury stock	--	--	1,863
Balance at end of year	--	--	--
Retained Earnings:
Balance at beginning of year	421,012	344,841	276,554
Net income	68,242	76,171	67,863
Reissuance of treasury stock at more than cost	--	--	424
Balance at end of year	489,254	421,012	344,841
Accumulated Other Comprehensive Income (Loss):
Balance at beginning of year	32,628	2,102	(22,987)
Other comprehensive income	25,375	30,526	25,089
Balance at end of year	58,003	32,628	2,102
Total Stockholders’ Equity	$  596,888	$ 495,807	$ 383,087
Comprehensive Income, net of tax:
Net income	$    68,242	$    76,171	$   67,863
Currency translation adjustments	18,573	28,620	25,241
Net unrealized holding gains (losses) net of tax of $3,870
in 2004, $1,053 in 2003 and $(32) in 2002	8,096	2,137	(59)
Reclassification adjustments for gains included in net income
net of tax of $623 in 2004, $108 in 2003 and $47 in 2002	(1,294)	(231)	(93)
Total Comprehensive Income	$   93,617	$ 106,697	$   92,952

The accompanying notes are an integral part of these statements.

6

Bio-Rad Laboratories, Inc.

Notes to Consolidated Financial Statements

________________________________________________________________

1.

SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all subsidiaries (Bio-Rad or the Company) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts report­ed in the financial statements and accompanying notes.  Actual results could differ from those estimates.

CHANGES IN PRESENTATION

Certain prior year amounts have been reclassified to conform to current year presentation.  The Company’s consolidated statements of income for the years ended December 31, 2003 and 2002 reflect the reclassification of discontinued operations during 2004 (see Note 5). The Company’s consolidated balance sheet as of December 31, 2003 reflects the reclassification of $83.2 million of auction rate securities and variable rate notes from cash and cash equivalents to short-term investments during 2004 (see Note 3).  Additionally, the Company has reclassified $21.2 million of deferred tax assets from short-term to long-term in 2003 to properly reflect the classification based on the underlying nature of the item creating the tax asset.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair market value.  

SHORT-TERM INVESTMENTS

Short-term investments consist of corporate, state and municipal securities with readily determinable fair market values and original maturities in excess of three months. Investments with maturities beyond one year may be classified as short-term based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company’s investments are classified as “available-for-sale” and accordingly are reported at fair value, with unrealized gains and losses, if material, reported as a component of stockholder’s equity. Unrealized losses are charged against income when a decline in the fair market value of an individual security is determined to be other than temporary. Realized gains and losses on investments are included in interest income.

7

CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents, short-tem investments and trade accounts receivable.  Cash and cash equivalents and short-term investments are placed with highly rated major financial institutions.  The Company performs credit evaluation procedures related to its trade receivables and with the exception of certain developing countries, generally does not require collateral.  As a result of increased risk in these developing countries, some Bio-Rad sales are subject to collateral letters of credit.  Credit risk is limited generally due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in coun­tries within the European Economic Community.  The Company does not currently anticip ate a credit risk associated with these receiv­ables.

ALLOWANCE FOR DOUBTFUL ACCOUNTS

The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness. Amounts later determined and specifically identified to be uncollectible are charged or written off against this reserve. This valuation allowance is reviewed quarterly to determine whether a change is warranted.

INVENTORY VALUATION

Inventories are valued at the lower of actual cost or market and include material, labor and overhead costs.  Management reviews the need for an inventory obsolescence reserve on a quarterly basis or, if warranted by the circumstances, more frequently.  In evaluating this reserve, technology changes, competition, customer demand and manufacturing quality are considered.

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are carried at historical cost. Included in property, plant and equipment is reagent rental equipment.  The Company provides these instruments to its customers for use with the Company's reagents.  Property, plant and equipment are assessed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  Buildings and leasehold improvements are amortized over 15-30 years or the lives of the leases or improvements, whichever is shorter.  With the exception of reagent rental equipment, which is amortized over a 1-5 year period, equipment is depreciated over 3-12 years.

Net capital expenditures include proceeds from the sale of property, plant and equipment of

$0.8 million and $1.1 million for the year ended December 31, 2004 and 2003, respectively.

8

GOODWILL

Goodwill, representing the excess of the cost over the net tangible and identifiable intangible assets of acquired businesses, is stated at cost.  Goodwill is assessed for impairment by applying a fair-value based test annually or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable (see Note 6).

INCOME TAXES

The Company accounts for income taxes under the asset and liability method which recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between carrying amounts and tax basis of assets and liabilities (see Note 8).

REVENUE RECOGNITION

Revenue is recognized when pervasive evidence of an arrangement exists, the price to the buyer is fixed and determinable, collectibility is reasonably assured and title has passed to the customer or product has been delivered absent specific contractual specifications.  Equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required contractually, has occurred.  Reagent agreements are a Diagnostic industry sales method that provides use of an instrument if the customer exclusively purchases the Company’s reagents to use on that instrument.  The Company has evaluated the reagent agreements and accounts for the contracts under the terms of the guidance set forth in EITF 00-21, Accounting for Revenue Arrangements with Multiple Deliverables.  All revenues that the Company earns under its reagent agreements are recognized when the reagent has b een delivered to the customer.  Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement or as service is performed, if not under contract.

SHIPPING AND HANDLING

The Company classifies all freight billed to customers as net sales.  Related freight costs are included in cost of goods sold.

SALES RETURNS AND WARRANTY

At the time the related revenue is recognized, a provision is recognized for estimated product returns.

The Company warrants certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon shipment of that equipment, the Company establishes, as part of cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty reserve.

9

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities, were as follows (in millions):

	2004	2003
January 1	$ 9.1	$ 7.1
Provision for warranty	10.4	12.0
Actual warranty costs	(9.4)	(10.0)
December 31	$ 10.1	$ 9.1

RESEARCH AND DEVELOPMENT

Internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed.  Purchased in-process research and development costs are expensed at the time of purchase.

FOREIGN CURRENCY

Balance sheet accounts of international subsidiaries are trans­lated at the current exchange rate as of the end of the account­ing period.  Income statement items are translated at average exchange rates.  The resulting translation adjustment is recorded as a separate component of stockholders' equity.  

Foreign currency transaction gains and losses are included in foreign exchange losses in the consolidated statement of income. Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of the Company’s subsidiary that recorded the transaction.

FORWARD EXCHANGE CONTRACTS

As part of distributing its products, the Company regularly enters into intercompany transactions.  The Company enters into forward foreign currency exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  The Company does not use derivative financial instruments for speculative or trading purposes.  In accordance with Statement of Financial Accounting Standard (SFAS) 133, Accounting for Derivative Instruments and Hedging Activities,  the Company does not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and related primarily to currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The resulting gains or losses offset exchange gains or losses on the relat ed receivables and payables, both of which are recorded as foreign exchange losses in the consolidated statement of income.  The cash flows related to these contracts are classified as cash flows from investing activities in the Statement of Cash Flows.

10

EMPLOYEE STOCK COMPENSATION PLANS

The Company maintains incentive and non-qualified stock option plans for officers and certain other key employees.  The Company also has an employee stock purchase plan that provides that eligible employees may contribute toward the purchase of the Company’s Class A common stock. These plans are described more fully in Note 10.

The Company applies the recognition and measurement principles of APB Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations in accounting for those plans.  No stock-based employee compensation expense is reflected in net income as all options granted under those plans had an exercise price equal to or greater than the market value of the underlying common stock on the date of grant.

Had compensation cost for the Company’s stock option and stock purchase plans been accounted for under SFAS 123, Accounting for Stock-Based Compensation, based on the assumptions and methods outlined in Note 10, the Company’s proforma net income and earnings per share would have been as follows (in millions, except per share data):

Year Ended December 31,
	2004	2003	2002

Net income, as reported	$ 68.2	$ 76.2	$ 67.9
Deduct: Total stock-based employee compensation
expense determined under fair value  methods
for all awards, net of related tax effects	(3.0)	(2.1)	(1.8)
Pro forma net income	$ 65.2	$ 74.1	$ 66.1
Earnings per share:
Basic-as reported	$ 2.65	$ 3.00	$ 2.70
Basic-pro forma	$ 2.54	$ 2.91	$ 2.63
Diluted-as reported	$ 2.58	$ 2.90	$ 2.61
Diluted-pro forma	$ 2.47	$ 2.82	$ 2.55

EARNINGS PER SHARE

The Company calculates basic earnings per share (EPS) and diluted EPS in accordance with

SFAS 128, Earnings per Share.  Basic EPS is computed by dividing net income (loss) by the weighted average number of common shares outstanding for that period.  Diluted EPS takes into account the effect of dilutive instruments, such as stock options, and uses the average share price for the period in determining the number of common stock equivalents that are to be added to the weighted average number of shares outstanding.  Common stock equivalents are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.  Treasury stock is not considered outstanding for purposes of calculating weighted average shares.

11

Weighted average shares used for diluted earnings per share include the dilutive effect of outstanding stock options to purchase 765,000, 894,000 and 917,000 shares for the years ended December 31, 2004, 2003 and 2002, respectively.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value.

The estimated fair value of Bio-Rad's financial instruments was as follows (in millions):

	Year Ended December 31,
	2004			2003
		Carrying	Fair		Carrying	Fair
		Amount	Value		Amount	Value
Notes receivable and other		$ 80.0	$ 104.2		$  52.9	$  58.3
Total long-term debt		$426.4	$450.5		$226.0	$256.2

Financial instruments (e.g., notes receivable) that have fair values based on discounted cash flows, market quotations, and other appropriate valuation techniques are included in Other assets.  Long-term debt has an estimated fair value based on quoted market prices for the same or similar issues.

For certain of the Company's financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, and accounts payable, the carrying amounts approximate fair value.

NEW FINANCIAL ACCOUNTING STANDARDS

In December 2004, the Financial Accounting Standards Board (FASB) issued SFAS 123R (Revised 2004), Share-Based Payment, which requires that the compensation cost relating to share-based payment transactions be recognized in financial statements based on alternative fair value models. The share-based compensation cost will be measured based on the fair value of the equity or liability instruments issued. The Company currently discloses pro forma compensation expense quarterly and annually (See Note 1).  Upon adoption, the pro forma disclosures previously permitted under SFAS 123 will no longer be an alternative to financial statement recognition. The provisions of SFAS 123R are effective as of the beginning of the first interim or annual reporting period that begins after June 15, 2005.  The Company is currently evaluating the method of adoption and the effect that the adoption of SFAS 123R will have on its financial p osition and results of operations.

12

In December 2004, the FASB issued SFAS 153, Exchanges of Nonmonetary Assets, an amendment of APB No. 29, Accounting for Nonmonetary Transactions. SFAS 153 requires exchanges of productive assets to be accounted for at fair value, rather than at carryover basis, unless (1) neither the asset received nor the asset surrendered has a fair value that is determinable within reasonable limits or (2) the transactions lack commercial substance. SFAS 153 is effective for nonmonetary asset exchanges occurring in fiscal periods beginning after June 15, 2005. The Company does not expect the adoption of this standard to have a material effect on its financial position, results of operations or cash flows.

In November 2004, the FASB issued SFAS 151, Inventory Costs -- an amendment of ARB No. 43, Chapter 4.   SFAS 151 amends the guidance in ARB No. 43 to clarify the accounting for abnormal amounts of idle facility expense, freight, handling costs, and wasted material (spoilage). SFAS 151 requires that these costs be recognized as current period charges regardless of whether they are abnormal. In addition, SFAS 151 requires that allocation of fixed production overheads to the costs of manufacturing be based on the normal capacity of the production facilities. The provisions of SFAS 151 are effective for inventory costs incurred during fiscal years beginning after June 15, 2005. The Company is investigating the impact this new standard may have on its consolidated financial position or results of operations.

In December 2003, the Securities and Exchange Commission (SEC) issued Staff Accounting Bulletin (SAB) 104, Revenue Recognition, which revises or rescinds portions of the interpretive guidance included in SAB 101, Revenue Recognition in Financial Statements, in order to make the guidance consistent with authoritative accounting and auditing guidance and with SEC rules and regulations. The principal revisions relate to the rescission of material no longer necessary because of private sector developments in United States generally accepted accounting principles. The adoption of SAB 104 did not have any impact on the Company's consolidated financial position or results of operations.

During April 2003, the FASB issued SFAS 149, Amendment of Statement 133 on Derivative Instruments and Hedging Activities.  SFAS 149 amends and clarifies accounting for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities under SFAS 133.  SFAS 149 was effective for contracts entered into or modified after June 30, 2003 and for hedging relationships designated after June 30, 2003 and did not have a material impact on the Company’s financial position or results of operations.

2.

ACQUISITIONS

In August 2004, the Company acquired the outstanding shares of MJ GeneWorks, Inc. and its subsidiaries, a life science company specializing in instruments and consumables used in modern biological research.  The total purchase price of $90.0 million included $7.0 million of net tangible assets, $40.5 million of goodwill and $42.5 million of intangible assets.  The Company paid $31.0 million in cash and assumed liabilities including $9.0 million in notes payable and capital leases and a $50.0 million litigation accrual (see Note 14).  Acquired in-process research and development of $13.7 million was charged to expense in the third quarter of 2004.  The allocation of the total purchase price to net tangible assets, goodwill and other intangible assets has been recorded at their fair market value based upon management estimates and third-party valuations.  The Company has included these operations in the Life Sci ence segment.

13

In March 2004, the Company purchased for cash the controls business of Hematronix, Inc. of Plano, Texas.  Bio-Rad acquired tangible and intangible assets and assumed certain liabilities for approximately $17 million.  Acquired in-process research and development of $0.9 million was charged to expense in the first quarter of 2004.  The Company has included these operations in the Clinical Diagnostics segment.

On March 31, 2003, the Company acquired the outstanding shares of Verdot Industrie of Riom, France for approximately $6 million.  The Company has included these operations in its Life Science segment. The Company has completed its evaluation of purchased assets, including intangible assets, and liabilities and did not assign any value to goodwill.

3. SHORT-TERM INVESTMENTS

Short-term investments consist of the following (in millions):

	December 31,
		2004	2003
Available-for-sale securities:
Auction rate securities		$146.5	$81.2
Certificate of deposit		4.0	--
Variable rate notes		8.4	2.0
U.S Agencies		7.0	--
Total short-term investments		$165.9	$ 83.2

Management classifies investments in marketable securities at the time of purchase and reevaluates such classification at each balance sheet date. Securities classified as available-for-sale are stated at fair value.  As of December 31, 2004, the short-term investments will mature within one year.

14

4. INVESTMENTS

The Company purchased shares of ordinary voting stock of Sartorius AG, of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries for approximately $11.0 and $10.4 million in 2004 and 2003, respectively.  At December 31, 2004, the Company owned approximately 23% of the outstanding voting shares of Sartorius.  The Sartorius family trust and Sartorius family members hold approximately 60% of the outstanding voting shares.  Bio-Rad does not have any representative or designee on Sartorius’ board of directors, nor does it have any other influence over the operating and financial policies of Sartorius.  Therefore, the Company accounts for this investment using the cost method.

In December 1997, Bio-Rad began investing in Instrumentation Laboratory, S.p.A. (IL), an Italian based clinical diagnostics company.  At December 31, 2004 and 2003, Bio-Rad held approximately 3% and 13% of the outstanding stock of IL, respectively.  A privately held company based in Spain controls approximately 96% of the outstanding stock of IL.  The most recently filed financial statements for IL available for review are as of November 30, 2003.  Based on a combination of many factors, including the lack of current financial information and IL's continued losses, the Company has determined that its investment has been other than temporarily impaired. As of December 31, 2004 and 2003, the Company valued its investment in IL at $4.0 million and $6.4 million, respectively.  This amount reflects a $2.4 million write-down in 2004 and a $3.0 million write-down in 2002, which has been recorded in Other income, net (see Note 11).  Although management believes that this investment is realizable, there is a possibility that future events may cause further impairment.

5.

DISCONTINUED OPERATIONS

On May 31, 2004, the Company sold a group of assets and transferred certain liabilities that comprise a substantial portion of the Company’s confocal microscopy product line to Carl Zeiss Jena GMBH. Proceeds of  $19.8 million were offset by net assets of $5.7 million, lease settlements of $6.7 million and severance, legal and other costs of $1.7 million resulting in a pre-tax gain of $5.7 million.  Payments on the lease liabilities will continue until 2008.  All other costs were settled by December 31, 2004.

As required by SFAS 144, Accounting for the Impairment or Disposal of Long-Lived Assets, with the disposition of this asset group, the sales and expenses related to this product line for current and prior periods have been reclassified as a separate line on the income statement titled “Discontinued Operations.”

The discontinued operations generated net sales of $6.3 million, $23.8 million and $27.7 million for the years ended December 31, 2004, 2003, and 2002, respectively.  The pre-tax operating losses attributable to the discontinued operations for the years ended December 31, 2004, 2003, and 2002 were $2.0 million, $1.7 million, and $0.8 million, respectively.

15

6.

GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

The Company adopted SFAS 142, Goodwill and Other Intangible Assets as of January 1, 2002, which provides that goodwill is no longer subject to amortization over its useful life.  Goodwill is subject to an annual assessment for impairment applying a fair-value based test.

As part of the acquisition of the controls business of Hematronix, Inc. in March 2004, (see Note 2) the Company added $3.2 million of goodwill and $9.3 million of intangible assets including in-process research and development.

In June 2004, the Company purchased $14.0 million of intangible assets related to licensing agreements. The Company paid $6.0 million upon acquisition and $4.0 million in the third quarter of 2004. The Company will pay the remaining $4.0 million over the next two years.

As part of the acquisition of MJ GeneWorks, Inc. and its subsidiaries in August 2004, (see Note 2) the Company added $40.5 million of goodwill and $42.5 million of intangible assets including $13.7 million of in-process research and development and $22.5 million of developed technology.

Goodwill balances have been included in corporate for segment reporting purposes in Note 15.

Other than goodwill, the Company has no intangible assets with indefinite lives.  Information regarding the Company’s identifiable purchased intangible assets is as follows (in millions):

	December 31, 2004
	Average	Carrying	Accumulated
	Useful Life	Amount	Amortization	Net
Developed Product Technology	11	$ 28.3	$ 2.5	$ 25.8
Licenses	16	14.1	0.4	13.7
Know How	8	9.9	2.8	7.1
Covenants Not to Compete	10	6.1	0.6	5.5
Patents	16	4.6	0.7	3.9
Customer Lists	6	1.7	0.3	1.4
Other	2	2.9	1.7	1.2
		$ 67.6	$  9.0	$58.6

	December 31, 2003
	Average	Carrying	Accumulated
	Useful Life	Amount	Amortization	Net
Know How	10	$   9.2	$  1.2	$   8.0
Patents	16	4.2	0.4	3.8
Other	2	0.7	0.2	0.5
		$ 14.1	$ 1.8	$ 12.3

16

Recorded intangible asset amortization expense for the years ended December 31, 2004 and 2003 was $6.9 million and $1.3 million, respectively.  Estimated intangible asset amortization expense (based on existing intangible assets) for the years ended December 31, 2005, 2006, 2007, 2008, and 2009 is $10.9 million, $10.2 million, $9.8 million, $8.5 million and $5.6 million, respectively.

7.

NOTES PAYABLE AND LONG-TERM DEBT

Notes payable include local credit lines maintained by the Company's subsidiaries aggregating approximately $62.3 million, of which $53.1 million was unused at December 31, 2004.  At December 31, 2003 these lines aggregated approximately $40.4 million, of which $30.2 million was unused.  The weighted average interest rate on these lines was 6.8% and 8.1% at December 31, 2004 and 2003, respectively.  Bio-Rad Laboratories, Inc. guarantees most of these credit lines.

The principal components of Long-term debt are as follows (in millions):

	December 31,
		2004	2003
7.5% Senior Subordinated Notes		$225.0	$ 225.0
6.125% Senior Subordinated Notes		200.0	--
Capitalized leases		1.4	1.0
		426.4	226.0
Less current maturities		(0.4)	(0.2)
Long-term debt		$ 426.0	$ 225.8

In December 2004, the Company sold $200.0 million principal amount of Senior Subordinated Notes due 2014 (“6.125% Notes”).  The notes pay a fixed rate of interest of 6.125% per year.  The Company has the right to repurchase up to 35% of the 6.125% Notes any time prior to December 15, 2007 upon any sale of the Company’s common stock at a specified redemption price plus accrued and unpaid interest and certain other charges.  Furthermore, the Company has the option to redeem any or all of the 6.125% Notes at various declining redemption prices or at 100% of the principal amount plus the “applicable premium” (as defined by the indenture) along with accrued and unpaid interest and certain other charges depending on the date redeemed.  The Company’s obligations under the 6.125% Notes are not secured, rank equal to other senior subordinated notes and rank junior to all the Company’s exis ting and future senior debt.

17

In August 2003, the Company sold $225.0 million principal amount of Senior Subordinated Notes due 2013. (“7.5% Notes”)  The notes pay a fixed rate of interest of 7.5% per year.  The Company has the right to repurchase up to 35% of the 7.5% Notes any time prior to August 15, 2006 upon any sale of the Company’s common stock at a specified redemption price plus accrued and unpaid interest and certain other charges.  Furthermore, the Company has the option to redeem any or all of the 7.5% Notes at various declining redemption prices or at 100% of the principal amount plus the “applicable premium” (as defined by the indenture) along with accrued and unpaid interest and certain other charges depending on the date redeemed. The Company’s obligations under the 7.5% Notes are not secured and rank equal to other senior subordinated notes and rank junior to all the Company’s existing and future s enior debt.

In 2002 and through July of 2003, the Company repurchased in the open market $17.3 million (par value) of its Senior Subordinated Notes due in 2007 (“11.675% Notes”) at an expense, including interest, unamortized issue costs and unamortized original issue discount of $2.5 million.  The remaining $88.7 million (par value) of 11.675% Notes were tendered and repurchased with a portion of the proceeds from the sale of the 7.5% Notes at an expense, including interest, unamortized issue costs and unamortized original discount of $11.6 million.  This expense is included in interest expense.

During 2003, the Company negotiated a five-year $150.0 million revolving credit facility to replace its $100.0 million revolving credit facility. The new credit facility is secured by substantially all of the Company’s personal property assets and the assets of its domestic subsidiaries and 65% of the capital stock of certain foreign subsidiaries. It is guaranteed by all of its existing and future domestic subsidiaries (other than immaterial domestic subsidiaries as defined for purposes of the new credit facility).  The Company terminated its existing credit facility simultaneously with the closing of its new facility.  Interest varies upon a number of factors including the duration of the specific borrowing and is based upon either the Eurodollar, the Federal Funds effective or the Company corporate based rate.

The credit facility, the 6.125% Notes and the 7.5% Notes require the Company, among other things, comply with certain financial ratios and covenants.  These covenants include a leverage ratio test, an interest coverage test and a consolidated net worth test.  There are also restrictions on the Company’s ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments, create liens and prepay subordinated debt.  The Company was in compliance with all financial ratios as of December 31, 2004 and 2003.

Maturities of long-term debt at December 31, 2004, are as follows: 2005 - $0.4 million; 2006 - $0.4 million; 2007 - $0.3 million; 2008 - $0.3 million; 2009 - $0.0 million; thereafter - $425.0 million.

18

8.  INCOME TAXES

The U.S. and international components of income before taxes are as follows (in millions):

	Year Ended December 31,
		2004	2003	2002
U.S.		$   3.5	$  43.6	$ 37.6
International		93.8	71.8	67.6
Income from continuing operations before taxes		$ 97.3	$ 115 .4	$ 105.2

The provision (benefit) for income taxes consists of (in millions):

	Year Ended December 31,
		2004	2003	2002
Current:
U.S. Federal		$  (3.8)	$  8.6	$ 11.8
International		36.4	33.8	31.0
U.S. State		1.4	1.1	1.0
		34.0	43.5	43.8
Deferred:
U.S. Federal		$   (6.2)	$  (3.0)	$  (2.3)
International		2.1	(1.8)	(4.2)
U.S. State		1.1	(0.6)	(0.6)
		(3.0)	(5.4)	(7.1)
Provision for income taxes		$  31.0	$  38.1	$   36.7

The Company's income tax provision differs from the amount computed by applying the U.S. federal statutory rate to income before taxes as follows:

	Year Ended December 31,
	2004		2003		2002
U. S. statutory tax rate	35	%	35	%	35	%
Foreign Sales Corporation/EIE tax benefit	(2)		(2)		(2)
Reduction in state tax benefits	2		--		--
Difference between U.S. and foreign tax rates
(net of foreign tax credits)	(4)		(1)		2
Loss carryforwards utilized	(1)		--		(1)
Foreign losses not benefited	3		1		2
Capital loss not benefited	1		--		1
Decrease in tax reserves	(1)		(1)		(1)
Other	(1)		1		(1)
Provision for income taxes	32	%	33	%	35	%

19

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

	Year Ended December 31,
	2004	2003
Deferred tax assets (current):
Reserves for inventory, warranty, and bad debt	$ 14.3	$ 15.8
Elimination of intercompany profit	8.8	8.7
Reserve for vacation pay	5.4	3.9
Other	7.4	7.0
Valuation allowance	(1.4)	(4.3)
	$ 34.5	$ 31.1
Deferred tax assets (non-current):
Tax benefit of loss carryforwards	8.4	10.1
Basis difference in investment	4.1	4.1
State tax credit carryforward	5.9	5.2
Amortization and depreciation	6.0	7.5
Retirement reserve	4.2	3.5
Other	14.5	8.0
Valuation allowance	(16.6)	(17.2)
	$ 26.5	$ 21.2
Deferred tax liabilities (non-current):
Deferred gain on condemnation	5.7	6.2
Foreign exchange unrealized gain	3.3	3.4
Development cost of Hercules facility	1.2	1.2
Amortization and depreciation	7.1	2.5
Other	7.5	1.5
	$ 24.8	$ 14.8

At December 31, 2004, Bio-Rad's international subsidiaries had combined net operating loss carryforwards of $22.2 million.  A portion of these loss carryforwards will expire in the following years: 2009 - $0.3 million and 2011 - $0.6 million.  The remainder of these loss carryforwards have no expiration date.  The utilization of these carryforwards is limited to the separate taxable income of each individual subsidiary.

20

At December 31, 2004, Bio-Rad had an unutilized domestic net operating loss carryforward of $13.5 million.  The loss carryforward will expire in the year 2018.  The utilization of the loss carryforward is limited to Bio-Rad's domestic taxable income.  At December 31, 2004, Bio-Rad had a California tax credit carryforward of $5.9 million.  The credit carryforward has no expiration date.  The utilization of the tax credit carryforward is limited to the extent Bio-Rad has California taxable income.

A valuation allowance is needed to reduce the deferred tax assets to an amount that is more likely than not to be realized. The net change in the valuation allowance in 2004 was a decrease of $3.5 million, primarily resulting from an increase in expected future earnings.    

Bio-Rad does not provide for taxes which would be payable if the cumulative undistributed earnings of its international sub­sidiar­ies, approximately $342 million at December 31, 2004, were remit­ted to the U.S. parent company.  Unless it becomes advantageous for tax or foreign exchange reasons to remit a subsidiary's earnings, such earnings are indefinitely reinvested in subsidiary operations.  The withholding tax and U.S. federal income taxes on these earnings, if remitted, would in large part be offset by tax credits.

9.

STOCKHOLDERS' EQUITY

The Company's outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in most respects except that Class A has limited voting rights.  Each share of Class A is entitled to one-tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect the balance of the directors.  Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.

10. STOCK OPTION AND PURCHASE PLANS

STOCK OPTION PLANS

The Company maintains stockholder approved incentive and non-qualified stock option plans for officers and certain other key employees.  No options have been issued to non-employees.

21

In April of 2003, stockholders approved the 2003 Stock Option Plan of Bio-Rad Laboratories, Inc. (the Plan).  The Plan authorizes the grant to employees of incentive stock options and non-qualified stock options.    A total of 1,675,000 shares have been reserved for issuance and may be of either Class A or Class B Common Stock.  At December 31, 2004, 1,370,250 shares remain available to be granted.

Under the Amended 1994 Stock Option Plan, the Company may grant options to its employees for up to 3,550,000 shares of common stock provided that no option shall be granted after March 1, 2004.  

Under the plans, Class A and Class B options are granted at prices not less than fair market value on the date of grant.  Generally, options granted have a term of 10 years and vest in increments of 25% per year over a four-year period on the yearly anniversary date of the grant.  For options granted after January 1, 2001, options vest in increments of 20% over a five-year period on the yearly anniversary date of the grant.  

Pro forma compensation costs are calculated for the fair value of the employees' purchase rights, which was estimated using the Black-Scholes model.  For purposes of the pro forma disclosures, the estimated fair value of the options granted is amortized to expense over the options' vesting period.  

The fair value of options granted was estimated using the Black-Scholes model with the following weighted average assumptions:

	Year Ended December 31,
	2004	2003	2002
Expected volatility	39%	37%	35%
Risk-free interest rate	2.73%	2.65%	3.99%
Expected life (in years)	4.3	4.2	4.2
Expected dividend	--	--	--

See Note 1 for a description of the effect of the pro forma compensation expense derived using the fair value method on the Company's results.

22

Activity under the 1994 and 2003 Plan’s are summarized below (amounts reported in the Price columns represent the weighted average exercise price):

	Year Ended December 31,
	2004		2003		2002
	Shares	Price	Shares	Price	Shares	Price
Outstanding at beginning of year	1,582,915	$20.04	1,591,832	$ 15.84	1,572,701	$11.80
Granted	306,990	53.82	302,993	35.71	379,500	28.85
Exercised	(221,759)	14.02	(222,699)	12.58	(350,549)	11.67
Forfeited	(33,629)	25.13	(89,211)	16.57	(9,820)	10.90
Expired	(3,800)	9.85	--	--	--	--
Outstanding at end of year	1,630,717	$27.14	1,582,915	$ 20.04	1,591,832	$ 15.84
Options exercisable at year-end	849,633	$15.22	780,415	$ 13.22	677,149	$ 12.39
Weighted average fair value of options
granted during the year	$18.74		$11.85		$9.75

The following summarizes information about stock options outstanding at December 31, 2004:

	Options Outstanding			Options Exercisable
Range of Exercise Prices	Number Outstanding at 12/31/04	Weighted Average Remaining Contractual Life (in years)	Weighted Average Exercise Price	Number Exercisable at 12/31/04	Weighted Average Exercise Price
$10.75-$11.94	477,726	5.37	$ 11.25	454,976	$ 11.25
$11.97-$28.61	491,329	4.32	20.72	317,332	16.54
$28.88-$53.50	425,766	7.80	37.52	77,325	33.23
$53.75-$58.85	235,896	9.10	53.92	--	--
	1,630,717	6.23	$ 27.14	849,633	$ 15.22

EMPLOYEE STOCK PURCHASE PLAN

The Company has an employee stock purchase plan that provides that eligible employees may contribute up to 10% of their compensation up to $25,000 annually toward the quarterly purchase of the Company's Class A common stock.  The employees purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  No compensation expense is recorded in connection with the plan.  The Company has authorized the sale of 1,890,000 shares of common stock under the plan.  

23

The Company sold 68,932 shares for $3.1 million, 71,314 shares for $2.4 million and 66,992 shares for $1.8 million under the plan to employees in 2004, 2003 and 2002, respectively.  The weighted average fair value of purchase rights granted in 2004, 2003 and 2002 was $10.81, $9.76 and $8.41, respectively.  At December 31, 2004, 200,307 shares remain authorized under the plan.

The fair value of the employees' purchase rights was estimated using the Black-Scholes model with the follow­ing assumptions:

	Year Ended December 31,
	2004	2003	2002
Expected volatility	20.91%	41.86%	44.19%
Risk-free interest rate	1.22%	0.93%	1.58%
Expected life (in years)	0.25	0.25	0.25
Expected dividend	--	--	--

See Note 1 for a description of the effect of the pro forma compensation expense derived using the

fair value method on the Company's results.   

11.

OTHER INCOME AND EXPENSE

Other income, net includes the following income (expense) components (in millions):

	Year Ended December 31,
		2004	2003	2002
Write-down of investments (Note 4)		$  (2.4)	$    --	$ (5.0)
Interest and investment income		6.6	3.2	4.3
Litigation settlement		1.9	--	--
Income from equity investee (Note 16)		3.1	--	--
Miscellaneous other items		1.9	(0.2)	1.4
Other income, net		$  11.1	$  3.0	$  0.7

24

12.  SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

	Year Ended December 31,
	2004	2003	2002
Income from continuing operations	$  66.3	$  77.3	$  68.5
Adjustments to reconcile income to
net cash provided by operating activities
(net of effects of acquisitions):
Depreciation	46.2	40.0	36.9
Amortization	10.0	2.0	1.1
Foreign currency economic hedge
transactions, net	(6.5)	15.0	2.3
Gains on dispositions of marketable securities	(1.9)	(0.3)	(0.1)
(Increase) decrease  in accounts receivable, net	(4.4)	10.0	(0.7)
Increase in inventories, net	(5.5)	(8.2)	(16.2)
Decrease (increase) in other current assets	3.5	(14.2)	(12.1)
Increase (decrease) in accounts payable
and other current liabilities	1.1	(1.6)	11.6
Decrease in income taxes payable	(2.8)	(5.6)	(6.9)
Increase (decrease) in deferred taxes	2.5	(8.0)	15.1
Loss on sale of spectroscopy business and
write-down of investments	2.4	--	5.0
Debt retirement costs on 11-5/8% bonds	--	9.5	--
Other	13.7	12.8	1.9
Net cash provided by continuing operations	124.6	128.7	106.4
Discontinued operations	(1.5)	(1.1)	(0.6)
Net cash provided by operating activities	$ 123.1	$ 127.6	$ 105.8

13.

COMMITMENTS AND CONTINGENT LIABILITIES

RENTS AND LEASES

Net rental expense under operating leases was $23.0 million in 2004, $23.0 million in 2003 and $19.5 million in 2002.  Leases are princi­pally for facilities and automobiles.  

25

Annual future minimum lease payments at December 31, 2004, under operating leases are as follows:  2005 - $22.7 million; 2006 - $15.4 million; 2007 - $9.7 million; 2008 - $5.3 million; 2009 - $2.8 million; subsequent to 2009 - $5.8 million.

DEFERRED PROFIT SHARING RETIREMENT PLAN

The Company has a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Direct­ors.  Bio-Rad has no liability other than for the current year's contribu­tion.  Contributions charged to income were $7.0 million, $6.5 million and $4.8 million in 2004, 2003 and 2002, respectively.

OTHER POST EMPLOYMENT BENEFITS

In several foreign locations the Company is statutorily required to provide a lump sum severance or termination indemnity to its employees.  Under these plans, the vested benefit obligation at December 31, 2004 and 2003 was $17.3 million and $14.3 million, respectively and have been included in Other long-term liabilities in the consolidated balance sheets.  These plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets to settle these obligations.

FOREIGN EXCHANGE CONTRACTS

The Company enters into forward foreign exchange con­tracts as an economic hedge against foreign currency denominated intercom­pany receiv­ables and payables.  At December 31, 2004, the Company had contracts maturing in January through March 2005 to sell foreign currency with a nominal value of $80.4 million and an unrealized loss of $0.1 million.  Contracts to purchase foreign currency had a nominal value of $23.0 million with an unrealized loss of $0.2 million.       

INSURANCE

The Company carries a deductible for workers' compensation and a portion of its group health insurance cost.  Accruals for losses are based on the Company's claims experience and actuarial assumptions followed in the insurance industry.  Should a greater amount of claims occur compared to the Company's estimates or cost of medical care increase beyond what has been anticipated, reserves recorded may not be sufficient and additional charges to income may be required.

26

LETTERS OF CREDIT

In the ordinary course of business, the Company is at times required to post letters of credit.  The letters of credit are issued by our banks to guarantee the Company’s obligations to insurance companies. The Company was contingently liable for approximately $4.6 million of standby letters of credit with banks as of December 31, 2004.

TAXES

Settlement of open tax years, as well as tax issues in other countries where the Company conducts its business, are not expected to have a material effect on the consolidated financial position or liquidity of the Company and, in the opinion of management, adequate provision has been made for income and franchise taxes for all years under examination or subject to future examination.

14.

LEGAL PROCEEDINGS  

Applera Corporation and Roche Molecular Systems filed a patent infringement case against MJ Research, Inc. and John and Michael Finney in the U.S. District Court for the District of Connecticut in June 1998.  On August 18, 2004, the Company acquired MJ Research through the acquisition of 100% of the stock of its parent company, MJ GeneWorks, Inc., from John and Michael Finney.  The complaint alleges that MJ Research is infringing on some Polymerase Chain Reaction (PCR) patents. In response to their claims, MJ Research filed counterclaims including, among others, allegations that Applera Corporation had licensed and enforced these patents through anticompetitive conduct in violation of federal and state antitrust laws.  A trial on these matters commenced in March 2004. The Court elected to hold the trial in two phases: a patent phase and an antitrust phase. In the patent phase, which has conclu ded, the jury found that MJ Research infringed three U.S. patents related to PCR process technology and three U.S. patents related to thermal cycler instrument technology. The jury found the infringement of four of the six patents to be willful.  In April 2004, the jury awarded damages to Applera Corporation and Roche Molecular Systems in the amount of $19.8 million.  Applera Corporation and Roche Molecular Systems intend to seek an enhancement of damages, including legal fees, since several infringements were found to be willful subjecting the Company to triple damages on a portion of the award.  Regarding the antitrust phase of the trial, the Court has ruled against MJ Research on all of its patent misuse defenses and federal antitrust counterclaims.  We expect the Court to dismiss all of MJ Research’s counterclaims, including the state antitrust and unfair competition claims, based on those rulings.  MJ Research is seeking reconsideration of the Court’s ruling on patent misuse.  MJ Research filed for chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Nevada on March 29, 2004.    On September 2, 2004, the Bankruptcy Court granted MJ Research’s motion to dismiss its chapter 11 bankruptcy case and the order dismissing the bankruptcy case became final on September 13, 2004.  In connection with these matters, the Company has established a $50.0 million litigation accrual.  See Note 2.

27

Applera Corporation filed four actions in the Regional Court of Düsseldorf, Germany during the period from August 2002 through September 2003 against MJ Research and others alleging infringement of four European patents relating to thermal cyclers.  The Company is also a defendant in one of the actions.  The suit seeks actual damages, costs and expenses and injunctive relief.  Three of the actions had a trial before the Düsseldorf court in April 2004. One of these actions has since been dismissed and another has been stayed pending a hearing in March 2005.  In May 2004, the Düsseldorf court issued an adverse ruling against MJ Research and the Company, which included an injunction against the Company and MJ Research from selling any real-time PCR instruments and reagents in Germany.  In December 2004, the European Patent Office revoked the patent and the injunctions aga inst MJ Research and the Company were lifted, allowing MJ Research and the Company to resume sales of real-time PCR thermal cyclers and reagents.  A decision on a separate action concerning Applera Corporation’s European patent relating to automated performance of PCR is expected in March 2005.

The Company is a defendant in an action in Japan which is similar to the action concerning the revoked European patent relating to real-time PCR.  Applera Corporation commenced this action against the Company on May 7, 2002.  The complaint alleges that the Company is infringing a Japanese patent which is a counterpart to the revoked European patent and seeks injunctive relief but not damages.  In November 2003, the Japanese court issued an adverse ruling against the Company which enjoins the Company from selling real-time PCR instruments and reagents in Japan.  The Company has appealed the decision and has also filed a separate action in the Japanese Patent Office seeking revocation of the Japanese patent.

The Company and MJ Research are also defendants in an action in the U.S. District Court for the District of Connecticut which is similar to the action concerning the European real-time PCR patent.  Applera Corporation commenced the action against the Company on   November 9, 2004.  The complaint alleges that the Company is infringing a U.S. patent which is a counterpart to the revoked European real-time PCR patent.  The complaint seeks damages and injunctive relief.

The Company is also party to various other claims, legal actions and complaints arising in the ordinary course of business.  The Company does not believe that any ultimate liability resulting from any of these other lawsuits will have a material adverse effect on its results of operations, financial position or liquidity.  However, the Company cannot give any assurance regarding the ultimate outcome of these lawsuits and their resolution could be material to the Company’s operating results for any particular period, depending upon the level of income for the period.

28

15.

SEGMENT INFORMATION

Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  Bio-Rad has two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer different products and services and require different marketing strategies.

The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research.  These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.

The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market.  These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians office laboratories, transfusion laboratories, and insurance and forensic testing laboratories.

The remainder of the Company's former Analytical Instruments segment is included in Other Operations.  The material product lines of this segment were sold in 2001 and 2000.

The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss used for corporate management purposes includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.

29

Information regarding industry segments at December 31, 2004, 2003 and 2002 and for the years then ended is as follows (in millions):

		Life		Clinical	Other
		Science		Diagnostics	Operations
Segment net sales	2004		$ 504.7	$ 576.4	$  8.9
	2003		456.2	514.8	8.6
	2002		401.8	455.4	7.8
Allocated interest expense	2004		$    8.0	$  12.1	$  0.1
	2003		6.7	9.6	0.1
	2002		8.8	12.4	0.1
Depreciation and amortization	2004		$  18.8	$  32.6	$  0.2
	2003		10.3	29.2	0.3
	2002		8.3	27.4	0.2
Segment profit (loss)	2004		$  31.4	$  60.1	$ (0.1)
	2003		73.2	59.8	(0.2)
	2002		76.0	41.9	(1.6)
Segment assets	2004		$ 277.5	$ 401.2	$   6.0
	2003		252.7	379.5	5.0
	2002		225.1	336.4	4.7
Capital expenditures	2004		$   24.1	$   34.6	$  0.1
	2003		36.2	30.7	0.1
	2002		10.9	29.7	0.1

The Life Science segment profit (loss) for 2004 includes $13.7 million of in-process research and development expense purchased as part of the MJ GeneWorks, Inc. acquisition.

30

The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to the Company's corporate headquarters.  The following reconciles total segment profit to consolidated income before taxes (in millions):

	Year Ended December 31,
		2004	2003	2002
Total segment profit		$  91.4	$ 132.8	$ 116.3
Other income, net		8.0	3.0	0.7
Foreign exchange losses		(2.4)	(4.1)	(5.4)
Costs related to bond redemption		--	(14.1)	(6.9)
Net corporate operating, interest
and other income and expense
not allocated to segments		0.3	(2.2)	0.5
Consolidated income before taxes
from continuing operations		$   97.3	$ 115.4	$ 105.2

The following reconciles total segment assets to consolidated total assets (in millions):

	December 31,
		2004		2003
Total segment assets		$  684.7	$ 637.2
Cash and other current assets		471.8	231.6
Net property, plant and equipment excluding
segment specific gross machinery and equipment		(16.4)	(34.2)
Goodwill		113.3	69.5
Other long-term assets		138.6	88.5
Total assets		$1,392.0	$ 992.6

31

The following presents sales to external customers by geographic area based primarily on the location of the use of the product or service (in millions):

	Year Ended December 31,
		2004	2003	2002
Europe		$    502.2	$  434.5	$ 363.4
Pacific Rim		168.2	159.8	142.6
United States		370.2	335.2	307.8
Other (primarily Canada and Latin America)		49.4	50.1	51.2
Total sales		$ 1,090.0	$ 979.6	$ 865.0

The following presents long-lived assets by geographic area based upon the location of the asset (in millions):

	Year Ended December 31,
		2004	2003	2002
Europe		$   57.7	$   48.4	$   31.8
Pacific Rim		8.0	7.5	7.2
United States		385.4	254.4	216.2
Other (primarily Canada and Latin America)		3.1	5.7	5.2
Total long-lived assets		$ 454.2	$ 316.0	$ 260.4

16.

QUARTERLY FINANCIAL DATA - (UNAUDITED)

Summarized quarterly financial data for 2004 and 2003 are as follows (in millions, except per share data):

	First Quarter		Second Quarter		Third Quarter		Fourth Quarter
2004
Net sales		$ 262.7		$ 260.5		$258.9		$ 307.9
Gross profit		149.3		149.7		142.8		168.3
Net income		22.0		22.9		6.3		17.0
Basic earnings per share		$0.86		$0.89		$0.24		$0.66
Diluted earnings per share		$0.83		$0.86		$0.24		$0.65
2003
Net sales		$ 240.4		$ 239.3		$ 241.8		$ 258.1
Gross profit		140.7		135.0		135.0		145.5
Net income		26.4		21.0		9.7		19.1
Basic earnings per share		$1.04		$0.83		$0.38		$0.75
Diluted earnings per share		$1.01		$0.80		$0.37		$0.73

32

In the fourth quarter of 2004, the Company refined its procedures to more accurately reflect the application of its revenue recognition policy, resulting in a decrease in net sales and net income of approximately $5.0 million and $1.7 million, respectively.  Also, in the fourth quarter of 2004, the Company adopted the equity method of accounting for one of its investments previously accounted for on the cost method.  The result was an increase in net income of $2.1 million.  Neither of these items had a significant effect on any prior quarter or fiscal year.

As stated in Note 5, the Company sold a group of the Life Science Division’s assets and transferred certain liabilities.  The quarterly financial data has been restated for the effects of this sale.  A reconciliation to previously reported quarterly financial data is as follows:

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
2004
Net sales	$ 262.7	$ 260.5	$ 258.9	$ 307.9
Sales of discontinued operations	3.9	2.4	--	--
Net sales previously reported	$ 266.6	$ 262.9	$ 258.9	$ 307.9
Gross profit	$ 149.3	$ 149.7	$ 142.8	$ 168.3
Gross profit of discontinued operations	1.5	0.5	--	--
Gross profit previously reported	$ 150.8	$ 150.2	$ 142.8	$ 168.3
2003
Net sales	$ 240.4	$ 239.3	$ 241.8	$ 258.1
Sales of discontinued operations	5.6	4.2	5.9	8.1
Net sales previously reported	$ 246.0	$ 243.5	$ 247.7	$ 266.2
Gross profit	$ 140.7	$ 135.0	$ 135.0	$ 145.5
Gross profit of discontinued operations	2.0	1.4	2.4	3.4
Gross profit previously reported	$ 142.7	$ 136.4	$ 137.4	$ 148.9

33

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

   Bio-Rad Laboratories Inc.

Hercules, California

We have audited the accompanying consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries (“the Company”) as of December 31, 2004 and 2003, and the related consolidated statements of income, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2004.  These financial statements are the responsibility of the Company’s management.  Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Bio-Rad Laboratories, Inc. and subsidiaries as of December 31, 2004 and 2003, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2004, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of the Company’s internal control over financial reporting as of December 31, 2004, based on the criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report (not presented herein) dated March 2, 2005 expressed an unqualified opinion on management’s assessment of the effectiveness of the Company’s internal control over financial reporting and an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

DELOITTE & TOUCHE LLP

San Francisco, California

March 2, 2005

34

MANAGEMENT’S DISCUSSION AND ANALYSIS

______________________________________________________________________

MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS

OF OPERATIONS AND FINANCIAL CONDITION

This discussion should be read in conjunction with the information contained in the Company's Consolidated Financial Statements and the accompanying notes which are an integral part of the statements.  References are to the Notes to Consolidated Financial Statements.

Other than statements of historical fact, statements made in this Annual Report include forward looking statements, such as statements with respect to the Company's future financial performance, operating results, plans and objectives that involve risk and uncertainties.  We have based these forward looking statements on our current expectations and projections about future events.  However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including among other things: our ability to successfully develop and market new products; our reliance on and access to necessary intellectual property; our substantial leverage and ability to service our debt; competition in and government regulation of the industries in which we operate; and the monetary policies of various countries.  We undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events, or otherwise.

Overview.  We are a multinational manufacturer and worldwide distributor of our own Life Science research and Clinical Diagnostics products.  Our business is organized into two primary segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and clinical diagnostics.  We sell more than 8,000 products and services to a diverse client base comprised of scientific research, healthcare, industry, education and government customers worldwide.  We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components.  Because our customers require replication of results from experiments and tests, we estimate that approximately 70% of our revenues are recurring.  Approximately 34% of our 2004 consolidated net sa les are from the United States, and approximately 66% are international sales, largely denominated in local currency with the majority of these sales in Euros, Yen and British Sterling.  As a result, our consolidated sales expressed in dollars benefit when the US dollar weakens and suffers when the dollar strengthens in relation to other currencies.  Currency fluctuations benefited our consolidated sales expressed in U.S. dollars in 2004 and 2003.  The market for reagents and apparatus remains good as growth rates have slowed in the global economic downturn but have not turned negative.  The market for large capital equipment in 2003 and 2004 declined from prior periods, as many pharmaceutical and biotechnology customers delayed or reduced their capital spending.  Bio-Rad is generally less impacted by capital spending as lower cost reagents and apparatus comprise more than 70% of product sales.

35

The following shows gross profit and expense items as a percentage of net sales:

	Year Ended December 31,
	2004	2003	2002
Net sales	100.0	100.0	100.0
Cost of goods sold	44.0	43.2	42.2
Gross profit	56.0	56.8	57.8
Selling, general and administrative expense	34.7	32.4	32.6
Product research and development expense,
excluding in-process research and development	9.9	9.3	9.2
Income from continuing operations	6.1	7.9	7.9
Discontinued operations	0.2	(0.1)	(0.1)
Net income	6.3	7.8	7.8

We intend that the discussion of our financial condition and results of operations that follow will assist you in understanding how accounting principles, policies and estimates effect our results, and the significant factors that caused changes in our operations and financial position for the years ended December 31, 2004 and 2003.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The accompanying discussion and analysis of the Company's financial condition and results of operations are based upon the consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (GAAP).  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and contingencies as of the date of the financial statements and reported amounts of revenues and expenses during the reporting periods.  The Company evaluates its estimates on an on-going basis.  The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  However, future events are subject to change and the best current estimates and assumptions routinely require adjustment.  Actual results could differ from these estimates.  The Company has determined that for the periods reported in their 2004 Annual Report that the following critical accounting policies and estimates, are critical in understanding the financial condition and results of operation of the Company.

36

Accounting for Income Taxes.  As part of the process of preparing Bio-Rad's consolidated financial statements management is required to estimate the Company's income taxes in each of the jurisdictions in which the Company operates.  This process involves estimating Bio-Rad's actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes.  These differences result in deferred tax assets and liabilities, which are included within the consolidated balance sheet.  Management must then assess the likelihood that the deferred tax assets will be recovered from future taxable income and to the extent management believes that recovery is not likely, a valuation allowance must be established.  To the extent management establishes a valuation allowance or increases this allowance in a period, an expense within the tax provision in the statement of operations must be included.

Significant management judgment is required in determining the provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against the net deferred tax assets.  The Company has recorded a valuation allowance of $18.0 million and $21.4 million as of December 31, 2004, and 2003 respectively due to uncertainties related to the Company's ability to utilize some of the deferred tax assets, primarily consisting of certain foreign net operating losses carried forward, before they expire.  The valuation allowance is based on management's current estimates of taxable income by the jurisdictions in which Bio-Rad operates and the period over which the deferred tax assets will be recoverable.  In the event that actual results differ from these estimates or these estimates are adjusted in future periods an additional valuation allowance may need to be established which would increase the tax provision, lowering income and impacting Bio-Rad’s financial position.  Should realization of these deferred assets previously reserved occur, the tax provision would decrease, raising income and positively impacting Bio-Rad’s financial position.

Valuation of Long-lived and Intangible Assets and Goodwill.  The Company assesses the impairment of identifiable intangibles, long-lived assets and related goodwill and enterprise level goodwill whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Projected future operating results and cash flows of the reporting units are used to establish the fair value used in evaluating the carrying value of the associated goodwill.  Factors the Company considers important which could trigger an impairment review include the following:

- significant under-performance relative to expected historical or projected future operating results;

- significant changes in the manner of use of the acquired assets or the strategy for the Company's overall business;

- significant negative industry or economic trends.

When the Company determines that the carrying value of intangibles, long-lived assets and related goodwill and enterprise level goodwill may not be recoverable based upon the existence of one or more of the above indicators of impairment, the Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in Bio-Rad's current business model.

37

In 2002, SFAS 142, Goodwill and Other Intangible Assets became effective.  The Company adopted SFAS 142 and ceased to amortize approximately $77.7 million of goodwill.  In lieu of amortization, the Company is required to perform an annual impairment review of goodwill.  For the years 2003 and 2004 that review indicated no impairment had taken place.  However, there can be no assurance that a material impairment charge will not be recorded in future periods.

Valuation of Inventories.   The Company values inventory at the lower of the actual cost to purchase and/or manufacture the inventory or the current estimated market value of the inventory.  The Company reviews inventory quantities on hand and records a provision for excess and obsolete inventory based primarily on an estimated forecast of product demand and production requirements for the next twelve months on a quarterly basis or, if warranted by the circumstances, more frequently.  In addition, our industry is characterized by technological change, frequent new product development and product obsolescence that could result in an increase in the amount of obsolete inventory quantities on hand.  Additionally, the Company's estimates of future product demand may prove to be inaccurate, in which case the Company may have understated or overstated the provision required for excess and obsolete inventory.  In the future, if inventory is determined to be overvalued, the Company would be required to recognize such costs in our cost of goods sold at the time of such determination.  Likewise, if inventory is determined to be undervalued, the Company may have over-reported cost of goods sold in previous periods and would be required to recognize such additional operating income at the time of sale.  Therefore, although the Company makes efforts to ensure the accuracy of its forecasts of future product demand, any significant unanticipated changes in demand or technological developments could have a significant impact on the value of its inventory and reported operating results.

Allowance for Doubtful Accounts.   The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The amount of the allowance is determined by analyzing known uncollectible accounts, the age of our receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ general credit-worthiness. Amounts later determined and specifically identified to be uncollectible are charged or written off against this reserve. This valuation allowance is reviewed on a quarterly basis to determine whether a provision or reversal is warranted.  Should the estimates be higher than the actual uncollectible accounts, the Company would report lower profitability when the estimates are made and higher profitability when the receivable is collected through negotiation or litigation.

Warranty Reserves.  The Company warrants certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon shipment of that equipment, the Company establishes, as part of cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.   A review is performed on a quarterly basis to assess the adequacy of our warranty reserve, and adjusted, if necessary.  The warranty percentage and accrual are based on actual experience and expected future costs to be incurred.  Should realized costs be higher than expected costs, costs of goods sold would be lower in the period of estimation and higher when realized.

38

Litigation Reserves. Estimated amounts for claims that are probable and can be reasonably estimated are recorded as liabilities in the consolidated balance sheets. The likelihood of a material change in these estimated reserves would be dependent on the possible outcome of settlement negotiations, regulatory or judicial review and the development of facts and circumstances in extended litigation which could change claims or assessments when both the amount and range of loss on some outstanding litigation is uncertain.  The Company is obligated to disclose in the footnotes of the financial statements when it is unable to make a reasonable estimate of the liability that could result from unfavorable outcomes in litigiation.  As events occur, the Company will assess the potential liability related to our pending litigation and revise our estimates. Such revisions in our estimates of the potential liability could material ly impact our results of operations and financial position.

CORPORATE RESULTS -- SALES, MARGINS AND EXPENSES

Bio-Rad net sales for the year 2004 were $1,090.0 million, an increase of 11.3% over the prior year.  The impact of a weakening US dollar throughout the year provided growth from foreign currency denominated net sales of approximately 5.8% for the full year.  

The Life Science segment had sales growth of 10.6% in 2004, benefiting from an approximate 5.8% increase due to foreign exchange.  Currency neutral sales growth of 4.8% was provided by the acquisition of MJ Research and the Company’s protein expression product lines.  Additionally, amplification and electrophoresis reagents product lines grew well.

Offsetting the sales growth of this segment is continued aggressive competitor pricing for the BSE test, continued general weakness related to some government grant spending (most notable Japan), and diminished capital equipment purchases by large pharmaceutical companies.

The Clinical Diagnostics segment had sales growth of 12.0% in 2004, benefiting from an approximate 5.7% increase due to foreign exchange.  Currency neutral sales growth of 6.3% was provided in several broad product lines of the Clinical Diagnostics segment.  The Company’s quality control products had significant growth both from the Hematronix acquisition and the growth of existing product offerings followed by diagnostic testing for autoimmune, diabetes and blood virus.

Bio-Rad net sales for the year 2003 were $979.6 million, an increase of 13.3% over the prior year after presenting the Company’s confocal microscopy operations, sold in May 2004, as discontinued operations.  The impact of a weakening US dollar throughout the year provided growth from net foreign currency denominated sales of approximately 8.8% for the full year.

The Life Science segment had sales growth of 13.6% in 2003, benefiting from an approximate 9.2% increase due to foreign exchange.  Life Science experienced sales growth in the areas of amplification and electrophoresis reagents.  Offsetting this growth was a currency neutral sales decline in the BSE test as a result of aggressive competitor price discounting.

39

The Clinical Diagnostics segment had sales growth of 13.0% in 2003, benefiting from an approximate 8.6% increase due to foreign exchange.  Product lines providing the 4.4% of currency neutral sales growth were quality control products and blood virus products.

The 2004 consolidated gross margins declined to 56.0% in the current year from 56.8% after presenting the confocal microscopy product line divestiture as discontinued operations on a consistent basis.  The decline in Life Science gross margins accounted for the decline for the Company as a whole.  Factors contributing to the Life Science decline were continued lower overall pricing on the BSE product line, increased intangible asset amortization from the MJ acquisition, as well as MJ integration costs, and lower than anticipated factory volumes not absorbing fixed factory overhead costs.  Clinical Diagnostics margins improved by about 1%.  Efficiency gains in factory performance have resulted in a general trend of improving Clinical Diagnostics margins.

The 2003 consolidated gross margins declined to 56.8% from 57.8% in the prior year.  The decline in gross margin for the Life Science segment accounted for the decline for the Company as a whole.  The BSE product line accounted for the majority of the decline as average selling price declined and costs to automate customer testing procedures were not fully recovered in an attempt to protect the Company’s existing market share.  Life Science manufacturing overhead costs also increased as planned spending levels exceeded the planned activity levels resulting in less efficient overhead absorption.  Clinical Diagnostics gross margins improved by approximately one-half of one percent.  Spending increases below the rate of sales growth have generally aided the small improvement in Clinical Diagnostics margins.

Consolidated selling, general and administrative expense was 34.7% for the year 2004 compared to 32.4% for the year 2003.  Both the Life Science and Clinical Diagnostics segments added expenses at a rate that exceeded sales growth, with a significant portion of the growth attributable to Life Science.  During 2004 Life Science had increased facility costs from moving into new facilities and consulting costs associated with the implementation of new distribution, manufacturing and financial software systems.  Costs also increased related to the MJ acquisition and legal matters associated with the gene expression product line.

The Company as a whole has seen significant increased costs associated with regulatory compliance especially Section 404 of Sarbanes-Oxley Act, but also global tax compliance and security and disaster recovery for the Company’s information technology infrastructure.  Personnel costs remain the largest element of SG&A expense and the increased cost for salary and wages, fringe benefits for existing, acquisition-related and current year increases to personnel all contributed to higher spending levels.

40

Consolidated selling, general and administrative expense for 2003 was 32.4% of sales, compared to 32.6% for the year ended 2002.  The Life Science segment added expenses at a rate of growth higher than sales.  Areas of emphasis were selling and marketing efforts in the segment’s protein function, protein separation and gene expression product lines.  SG&A expenses were not reduced in food safety as a means to respond in the short term to competitive pressures maintaining Bio-Rad’s market leading position.  The Clinical Diagnostics segment grew SG&A at a lower rate than sales growth and accounts in large part for their improved segment profitability.  The Company also made investments in financial and tax compliance to improve future profitability.  

Excluding $14.6 million of purchased in-process R&D from both the Hematronix and MJ Research acquisitions, product research and development expense (R&D) in 2004 rose to 9.9% of sales from 9.3% in 2003.  The significant increase in spending levels occurred in Life Science in the areas of protein separation and function and food safety.  Increased spending levels in Clinical Diagnostics are attributable to the recently announced FDA clearance for the Bio-Plex 2200^TM, an immunoassay platform that employs multiplexing technology. Clinical Diagnostics continues to invest in expanding its quality control products and blood virus diagnostic tests.  Bio-Rad plans to reinvest between 9% and 10% of sales in research and development annually to support sales growth.

Product research and development expense in 2003 rose to 9.3% of sales. In absolute dollars each segment had growth with Life Science increasing more than Clinical Diagnostics.  Life Science concentrated on proteomics, process chromatography, food testing and microarray technology.  Clinical Diagnostics concentrated on automation for the serology, autoimmune and blood virus products as well as the segment’s quality control products.

CORPORATE RESULTS

Interest expense declined in 2004 to $20.2, a decrease of $10.8 million.  The year 2004 is representative of approximately $251.6 million of average borrowings, consisting largely of the September 2003, 7.5%, 10 year bonds plus the amortization of bond origination fees and interest on local foreign lines of credit.  In December 2004, the Company borrowed an additional $200.0 million in a private placement of 10 year senior subordinated notes at 6.125%.  This additional borrowing will cause 2005 interest expenses to increase by approximately $12.5 million including the amortization of bond origination fees.  For 2004, the 6.125% 2004 bonds were outstanding for nine days.

Interest expense increased to $31.0 million in the year 2003.  Included in the current year’s interest cost is $14.6 for the open market repurchase and tendering of $106.0 million of Bio-Rad’s 11-5/8% Senior Subordinated Notes due 2007 and the refinancing of the Company’s primary credit facility.  These costs include a premium to repurchase the notes, and the expensing of unamortized debt issue costs and original issue discount.

41

Foreign exchange losses for 2004 and 2003 decreased by $1.7 and $1.4 million, respectively, when compared to prior years.  All years include the net cost of Bio-Rad’s economic hedging program valuing open option contracts to fair market value at period end and the revaluation of intercompany receivables and payables for the established European, Asian and North America currencies.

Other income and expense for the year 2004 includes $4.6 million of interest and dividends generated by the Company’s net cash position and notes receivable.  The Company also settled by negotiation and received cash payments of $3.3 million in two matters that originated prior to 2002.  First was a $1.9 million settlement with an outside legal firm which represented the Company in the mid 1990s.  The second settlement was with Digilab LLC for contested transition services settled in connection with the sale of the Company’s spectroscopy product line in October 2001.  The Company additionally recorded a write-down of $2.4 million for an other than temporary impairment of its investment in Instrumentation Laboratories, an Italian diagnostic company in which it holds a 3% stake, and recorded $3.1 million of other income associated with an equity method investee, a Japanese equipment manufacturer in which it holds a 40% stake.

Bio-Rad’s consolidated effective tax rate was 32%, 33% and 35% in 2004, 2003 and 2002, respectively.  The tax rate for all years reflects the utilization of loss carryforwards, foreign sales corporation benefits, and foreign tax credits.  The largest component in the 2004 and 2003 year over year decline in the tax rate is the difference between U.S. and foreign tax rates, net of foreign tax credits.

FINANCIAL CONDITION

Historically, the Company's principal capital requirement was for working capital to fund its internal growth.  Management assesses Bio-Rad’s liquidity in terms of its ability to generate cash to fund its operations and make acquisitions.  The relevant factors that effect liquidity are cash flows from operations, capital expenditures, acquisition opportunities, Common Stock repurchases, the adequacy of available bank lines of credit and the ability to raise long-term capital by borrowing in the debt markets with satisfactory terms and conditions.

At December 31, 2004, the Company had available $361.6 million in cash, cash equivalents and short-term investments, and $53.1 million under international lines of credit.  Under the $150.0 million restated and amended Revolving Credit Facility the Company has $145.4 million available with $4.6 million reserved for standby letters of credit issued by our banks to guarantee the Company’s obligations to certain insurance companies.  Management believes that this availability, together with cash flow from operations, will be adequate to meet the Company's current objectives for operations, research and development, capital additions for plant, equipment and systems and an acquisition consistent with opportunities presently available.

42

CASH FLOW FROM OPERATIONS

Net cash provided by operations was $123.1 million, $127.6 million and $105.8 million in 2004, 2003 and 2002 respectively.  The decrease is primarily due to increased spending with suppliers and employees in operating the business.  This decline in operating cash flows was caused by higher regulatory compliance, facility, and personnel costs, offset by lower income tax payments and miscellaneous receipts including settlements of disputed legal charges and the collection of a disputed non-trade receivable.  The increase in receivables and inventory after elimination of foreign currency and acquisitions was in line with our sales growth and not a significant factor to declining cash flows from operations.

Bio-Rad’s management regularly reviews the allowance for uncollectible receivables and believes net accounts receivable are fully realizable.  Management routinely reviews inventory for the impact of obsolesence and changes in market prices caused by the introduction of new products, technologies and in government reimbursement policies.

CASH FLOW FROM INVESTING ACTIVITIES

Net capital expenditures in 2004 totaled $60.5 million, compared to $69.0 million and $42.2 million in 2003 and 2002, respectively.  The cost to complete a new 160,000 square foot building on our Hercules campus was approximately $26 million of which $23.1 million was incurred in 2003.  Complete occupancy occurred at the end of the first quarter of 2004.  A principal expenditure in all years was clinical diagnostics equipment placed with customers to be used with the Company's clinical diagnostics reagents.  For 2004 this amount represents $15.9 million of capital additions.  The Company continues to invest in business systems to standardize distribution software and enhance data communication.  Other expenditures were made for the replacement and improvement of production equipment and facilities to meet the necessary Good Manufacturing Practices, (GMP) mandated by the Food and Drug Administration (FDA) for Clinical Diagnostics and to meet the requirements of other regulatory bodies as well as many customers in the Life Science market.

Net cash used in investing activities was $186.3 million for the year 2004.  Payments for acquisitions include cash paid for the acquisition of Hematronix in the first quarter of 2004, an increase in the Company’s investment in Sartorius in the second quarter of 2004, and the acquisition of MJ Geneworks in the third quarter of 2004.  Proceeds from divestitures represents the cash received from the divestiture of the confocal microscopy product line.  The $88.9 million of net purchases of marketable securities and investments represents the temporary placement of funds not being used in operations.  Cash and short-term investment in part represents the Company’s resources available to do an acquisition before drawing on its available credit facilities and incurring additional debt.  Actual acquisition spending, however, may vary depending upon the availability and timing of a suitable candidate.

43

CASH FLOW FROM FINANCING ACTIVITIES

Net cash flow provided from financing was $193.2 million for 2004.  During the fourth quarter of 2004, the Company borrowed $200 million at 6.125% due 2014 in a private placement.  The funds were invested in cash equivalents and short-term investments to be available for a possible acquisition.  A specific target has not been identified but the Company continually discusses strategic and tactical opportunities with owners and principals representing possible acquirees.  Net borrowings under lines of credit represent repayments of the credit facility Bio-Rad assumed in the MJ Geneworks acquisition.

The Company completed three significant financing transactions during 2003. These transactions were the completion of a $150.0 million revolving credit facility, the placement of $225.0 million aggregate principal amount of Senior Subordinated Notes in a private offering and completion of a cash tender offer to retire all of its outstanding 11-5/8% Senior Subordinated Notes due in 2007.

The $150.0 million revolving credit facility is secured by substantially all of the Company’s personal property assets and the assets of its domestic subsidiaries and 65% of the capital stock of certain foreign subsidiaries, and is guaranteed by all of its existing and future domestic subsidiaries (other than immaterial domestic subsidiaries as defined for purposes of the new credit facility).  

On August 11, 2003 the Company completed the sale of $225 million aggregate principal amount of its 7.5% Senior Subordinated Notes due 2013 in a private offering.  The Company used $98.2 million of the net proceeds from this offering to fund the purchase of the outstanding 11-5/8% Senior Subordinated Notes due 2007 pursuant to a tender offer completed on September 30, 2003 with the remainder available for general corporate purposes, which may include acquisitions.

The $225.0 million private placement has been exchanged for the new 7.5% Exchange Notes that have been registered under the Securities Act of 1933, as amended, or applicable state securities laws.  This transaction was completed on October 30, 2003, with the new Exchange Notes being virtually identical in all material respects to the 7.5% private placement.

The Board of Directors has authorized the Company to repurchase up to $18 million of the Company's common stock over an indefinite period of time.  Through December 31, 2004, the Company has cumulatively repurchased 1,179,272 shares of Class A Common Stock and 60,000 shares of Class B Common Stock for a total of $14.7 million.  The Company's credit agreements restrict the Company's ability to repurchase its own stock.  There were no share repurchases made during 2003 or 2004.  The repurchase is designed to improve shareholder value and to satisfy the Company's obligations under the employee stock purchase and stock option plans.

44

CONTRACTUAL OBLIGATIONS

The following summarizes certain of our contractual obligations as of December 31, 2004 and the effect such obligations are expected to have on our cash flows in future periods (in millions):

Contractual Obligations	Total	Less than One Year	1-3 Years	3-5 Years	More than 5 Years
Long-term debt,
including current portion (1)	426.4	0.4	0.7	0.3	425.0
Operating lease obligations (2)	61.7	22.7	25.1	8.1	5.8
Purchase obligations (3)	12.7	9.5	1.4	0.9	0.9
Long-term liabilities	29.0	--	14.7	2.9	11.4

⁽¹⁾

These amounts represent expected cash payments, include capital lease obligations and are included in our Consolidated Balance Sheets.  See Note 7 of the Consolidated Financial Statements for additional information about our debt.

⁽²⁾

Operating lease obligations are described in Note 13 of the Consolidated Financial Statements.

⁽³⁾

Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on the Company and that specify all significant terms.  Purchase obligations exclude agreements that are cancelable without penalty.

FINANCIAL RISK MANAGEMENT

Bio-Rad uses derivative financial instruments to reduce the Company's exposure to fluctuations in foreign exchange rates and, on occasion, interest rates.  No derivative financial instruments are entered into for the purpose of speculating or trading.  Company policy limits all derivative positions exclusively to reducing risk by hedging an underlying economic exposure.  These derivative investments do not qualify for hedge accounting treatment under SFAS 133, Accounting for Derivative Instruments and Hedging Activities.  Derivative instruments used in these transactions will be valued at fair value and changes in fair value will be included in reported earnings.

Bio-Rad operates and conducts business in many countries and is exposed to movements in foreign currency exchange rates.  Additionally, Bio-Rad's consolidated net equity is impacted by the conversion of the net assets of international subsidiaries for which the functional currency is not the U.S. Dollar.  Foreign currency exposures are managed on a centralized basis by the Company's Treasury Department.  This allows for the netting of natural offsets and lowers transaction costs and exposures.  Bio-Rad currently makes more than 60% of its sales outside the United States and weakening in one currency can often be offset by strengthening in another currency.

45

Bio-Rad typically enters into forward exchange contracts to sell its foreign currency.  Contracts primarily in British Sterling, Japanese Yen and the Euro, are entered into typically for 30 to 60 days.  Bio-Rad records the change in the value of its foreign currency intercompany receivables and payables as a foreign exchange gain or loss on its statements of income along with the change in the fair market value of the forward exchange contract used as an economic hedge of that asset or liability.

Bio-Rad uses sensitivity analysis to assess the market risk associated with its foreign currency exchange risk.  Market risk is the potential change in fair value of derivative positions from an adverse movement in currency exchange rates.  A 10% adverse loss on quoted foreign currency exchange rates would result in an approximate $10 million loss.  This impact of a change in exchange rates excludes the offset derived from the change in the Company’s underlying assets and liabilities, which could reduce the effect to zero.

The Company's long-term debt consists primarily of fixed rate instruments. Bio-Rad uses sensitivity analysis to assess the market risk associated with its interest rate risk.  As of December 31, 2004, the Company’s interest rate risk was not significant.    

46

EX-21

EXHIBIT 21.2

LISTING OF SUBSIDIARIES

JURISDICTION OF

SUBSIDIARY

ORGANIZATION

Bio-Rad Laboratories Pty. Limited

Australia

Bio-Rad Laboratories Ges.m.b.H.

Austria

Bio-Rad Laboratories S.A- N.V.

Belgium

RSL N.V.

Belgium

Bio-Rad Laboratorios Brasil Ltda.

Brazil

Bio-Metrics Properties, Limited

California, USA

Bio-Rad Laboratories (Israel) Inc.

California, USA

Bio-Rad Pacific Limited

California, USA

Bio-Rad Laboratories (Canada) Limited

Canada

Bio-Rad Laboratories (Shanghai) Limited

China

Bio-Rad spol. sr.o.

Czech Republic

MJ Bioworks, Inc.

Delaware, USA

Bio-Rad France Holding

France

Bio-Rad Pasteur

France

ADIL Instruments

France

Bio-Rad Laboratories S.A.S.

France

Bio-Rad Verdot

.

France

Bio-Rad

France

Bio-Rad Laboratories G.m.b.H.

Germany

Bio-Rad Management G.m.b.H.

Germany

Bio-Rad Laboratories E.P.E

Greece

Bio-Rad China Limited

Hong Kong

Bio-Rad Hungary Trading Ltd.

Hungary

Bio-Rad Laboratories(India)Private Limited

India

Bio-Rad Laboratories S.r.l.

Italy

Nippon Bio-Rad Laboratories K.K.

Japan

Bio-Rad Fujirebio Inc.

Japan

MJ Japan Limited

Japan

Bio-Rad Korea Limited

Korea

International Marketing Ventures, Limited

Maryland, USA

MJ Research, Inc.

Massachusettes, USA

Bio-Rad, S.A.

Mexico

Bio-Rad Laboratories B.V.

The Netherlands

Bio-Rad Polska Sp. z o.o.

Poland

Bio-Rad Laboratoires-Aparelhos e Reagentes

  Hospitalares, LDA

Portugal

Bio-Rad Laboratorii OOO

Russia

Bio-Rad Laboratories (Singapore) Pte. Limited

Singapore

Bio-Rad Laboratories (Pty) Limited

South Africa

Bio-Rad Laboratories S.A.

Spain

Bio-Rad Laboratories AB

Sweden

Bio-Rad Laboratories AG

Switzerland

Bio-Rad Laboratories Taiwan Limited

Taiwan

Bio-Rad Laboratories Limited

Thailand

Bio-Rad Laboratories Europe Limited

United Kingdom

Bio-Rad Laboratories Limited

United Kingdom

Bio-Rad Micromeasurements Limited

United Kingdom

Bio-Rad Microscience Limited

United Kingdom

MJ Geneworks, Inc.

Wisconsin, USA

EX-23

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statements No.   33-53335 and 33-53337 of Bio-Rad Laboratories, Inc. and subsidiaries on Form S-8 of our reports dated March 2, 2005, relating to the consolidated financial statements and financial statement schedule of Bio-Rad Laboratories, Inc. and subsidiaries and management’s report on the effectiveness of internal control over financial reporting, appearing in this Annual Report on Form 10-K of Bio-Rad Laboratories, Inc. for the year ended December 31, 2004.

DELOITTE & TOUCHE LLP

San Francisco, California

March 2, 2005

2

EX-31

Exhibit 31.1

Certification of Chief Executive Officer Required By

Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.

I have reviewed this annual report on Form 10-K of Bio-Rad Laboratories, Inc.

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f))for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period

covered by this report based on such evaluation; and

        (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  _March 2, 2004	/s/ Norman D. Schwartz
	Norman Schwartz
	Chief Executive Officer

EX-31

Exhibit 31.2

Certification of Chief Financial Officer Required By

Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Christine Tsingos, certify that:

1.

I have reviewed this annual report on Form 10-K of Bio-Rad Laboratories, Inc.

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f))for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

        (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  March 2, 2004	/s/ Christine A. Tsingos
	Christine A. Tsingos
	Vice President,
	Chief Financial Officer

EX-32

Exhibit 32.1

Certification of Periodic Report

I, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

(1)

the Annual Report on Form 10-K of the Company for the year ended December 31, 2004 (the “Report”) fully complies with the requirements of Section 13 of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  March 2, 2005	/s/ Norman Schwartz
	Chief Executive Officer

2

EX-32

Exhibit 32.2

Certification of Periodic Report

I, Christine A. Tsingos, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

(1)

the Annual Report on Form 10-K of the Company for the year ended December 31, 2004 (the “Report”) fully complies with the requirements of Section 13 of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 2, 2005	/s/ Christine A. Tsingos
	Vice President, Chief Financial Officer

2